CA1117117A - 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same - Google Patents
2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the sameInfo
- Publication number
- CA1117117A CA1117117A CA000336130A CA336130A CA1117117A CA 1117117 A CA1117117 A CA 1117117A CA 000336130 A CA000336130 A CA 000336130A CA 336130 A CA336130 A CA 336130A CA 1117117 A CA1117117 A CA 1117117A
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- methyl
- isopropyl
- chemical equivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 2-methyl-dihydropyridine compound Chemical class 0.000 title claims abstract description 225
- 238000000034 method Methods 0.000 title claims description 142
- 238000002360 preparation method Methods 0.000 title description 8
- 239000008194 pharmaceutical composition Substances 0.000 title description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 63
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract description 15
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims abstract description 7
- 125000004849 alkoxymethyl group Chemical group 0.000 claims abstract description 7
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims abstract description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims abstract description 5
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims abstract description 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract description 5
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims abstract description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 130
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 49
- 239000000126 substance Substances 0.000 claims description 47
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims description 6
- 239000012024 dehydrating agents Substances 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000000304 vasodilatating effect Effects 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 4
- FFXNQICQXPTWGP-UHFFFAOYSA-N 2-methyl-1,2-dihydropyridine Chemical class CC1NC=CC=C1 FFXNQICQXPTWGP-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 239000002253 acid Substances 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940022682 acetone Drugs 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- KTCNGKASVZVXHT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CNC1 KTCNGKASVZVXHT-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
- MBELGTLJWJJGLF-UHFFFAOYSA-N 1,4-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CNC=CC1 MBELGTLJWJJGLF-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 240000001812 Hyssopus officinalis Species 0.000 description 3
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- ZPIBNRBMPJVTSK-UHFFFAOYSA-N 3-oxo-2-[[2-(trifluoromethyl)phenyl]methylidene]butanoic acid Chemical compound CC(=O)C(C(O)=O)=CC1=CC=CC=C1C(F)(F)F ZPIBNRBMPJVTSK-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical group NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
- ZMOHEDHLCNBPAN-UHFFFAOYSA-N 1-methyl-4-pyridin-4-yl-4H-pyridine-3-carboxylic acid Chemical compound CN1C=C(C(C=C1)C1=CC=NC=C1)C(=O)O ZMOHEDHLCNBPAN-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
- RNLWFWOHIRPWLT-UHFFFAOYSA-N 2-(dipropoxymethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=C(C)NC(C(OCCC)OCCC)=C(C(O)=O)C1C1=CC=CC([N+]([O-])=O)=C1 RNLWFWOHIRPWLT-UHFFFAOYSA-N 0.000 description 1
- JKNQPDQEKDQZLD-UHFFFAOYSA-N 2-methyl-4-(2-methylphenyl)-1,4-dihydropyridine-3-carboxylic acid Chemical compound CC=1NC=CC(C1C(=O)O)C1=C(C=CC=C1)C JKNQPDQEKDQZLD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- JOXAWSWPPKXDNK-UHFFFAOYSA-N 4-(2,4-dichlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C=O)NC(C)=C(C(O)=O)C1C1=CC=C(Cl)C=C1Cl JOXAWSWPPKXDNK-UHFFFAOYSA-N 0.000 description 1
- FXXDHXKBVVQITN-UHFFFAOYSA-N 4-(2-chlorophenyl)-6-(hydroxymethyl)-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(CO)NC(C)=C(C(O)=O)C1C1=CC=CC=C1Cl FXXDHXKBVVQITN-UHFFFAOYSA-N 0.000 description 1
- YONNCDUESFJDFD-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-6-(dimethoxymethyl)-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=C(C)NC(C(OC)OC)=C(C(=O)OC)C1C1=CC=C(Cl)C(Cl)=C1 YONNCDUESFJDFD-UHFFFAOYSA-N 0.000 description 1
- QLSLIALPTOGRJF-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C=O)NC(C)=C(C(O)=O)C1C1=CC=C(Cl)C(Cl)=C1 QLSLIALPTOGRJF-UHFFFAOYSA-N 0.000 description 1
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 1
- VAJJRIAQVQVQFK-UHFFFAOYSA-N 5-ethoxycarbonyl-6-formyl-2-methyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(C=O)NC(C)=C(C(O)=O)C1C1=CC=CC=C1C(F)(F)F VAJJRIAQVQVQFK-UHFFFAOYSA-N 0.000 description 1
- NDWYFWLHNKFUMC-UHFFFAOYSA-N 6-(diethoxymethyl)-5-ethoxycarbonyl-2-methyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=C(C)NC(C(OCC)OCC)=C(C(=O)OCC)C1C1=CC=CC=C1C(F)(F)F NDWYFWLHNKFUMC-UHFFFAOYSA-N 0.000 description 1
- UDYDPGCMQAASPL-UHFFFAOYSA-N 6-(dimethoxymethyl)-5-methoxycarbonyl-2-methyl-4-(2-methylphenyl)-1,4-dihydropyridine-3-carboxylic acid Chemical compound OC(=O)C1=C(C)NC(C(OC)OC)=C(C(=O)OC)C1C1=CC=CC=C1C UDYDPGCMQAASPL-UHFFFAOYSA-N 0.000 description 1
- KJITYNJYOKHJTJ-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxycarbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(CO)NC(C)=C(C(O)=O)C1C1=CC=CC=C1 KJITYNJYOKHJTJ-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- SJBPYMYIHGVGRI-UHFFFAOYSA-N 6-cyano-4-(3,4-dimethoxyphenyl)-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(O)=O)C1C1=CC=C(OC)C(OC)=C1 SJBPYMYIHGVGRI-UHFFFAOYSA-N 0.000 description 1
- WHFGHQAHOXSCJY-UHFFFAOYSA-N 6-cyano-5-ethoxycarbonyl-2-methyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid Chemical compound CCOC(=O)C1=C(C#N)NC(C)=C(C(O)=O)C1C1=CC=CC=C1C(F)(F)F WHFGHQAHOXSCJY-UHFFFAOYSA-N 0.000 description 1
- JKVCTVMWIKAFGN-UHFFFAOYSA-N 6-cyano-5-methoxycarbonyl-2-methyl-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(O)=O)C1C1=CC=CC=C1C(F)(F)F JKVCTVMWIKAFGN-UHFFFAOYSA-N 0.000 description 1
- BYYMXXHVNRKXES-UHFFFAOYSA-N 6-cyano-5-methoxycarbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(O)=O)C1C1=CC=CC=C1 BYYMXXHVNRKXES-UHFFFAOYSA-N 0.000 description 1
- JKHYEHHIENMVEB-UHFFFAOYSA-N 6-cyano-5-methoxycarbonyl-2-methyl-4-thiophen-2-yl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(O)=O)C1C1=CC=CS1 JKHYEHHIENMVEB-UHFFFAOYSA-N 0.000 description 1
- QTBWNRXURVUKBD-UHFFFAOYSA-N 6-formyl-5-methoxycarbonyl-2-methyl-4-pyridin-4-yl-1,4-dihydropyridine-3-carboxylic acid Chemical compound COC(=O)C1=C(C=O)NC(C)=C(C(O)=O)C1C1=CC=NC=C1 QTBWNRXURVUKBD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 150000001241 acetals Chemical group 0.000 description 1
- 150000004729 acetoacetic acid derivatives Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- HUHKWTJDQOHHGL-FPLPWBNLSA-N ethyl (z)-2-amino-4,4-diethoxybut-2-enoate Chemical compound CCOC(OCC)\C=C(/N)C(=O)OCC HUHKWTJDQOHHGL-FPLPWBNLSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- CTAASNAJQFOGDU-UHFFFAOYSA-N methyl 2-[(3,4-dimethoxyphenyl)methylidene]-4,4-dimethoxy-3-oxobutanoate Chemical compound COC(OC)C(=O)C(C(=O)OC)=CC1=CC=C(OC)C(OC)=C1 CTAASNAJQFOGDU-UHFFFAOYSA-N 0.000 description 1
- UWPTXKIEBAMPKY-UHFFFAOYSA-N methyl 4,4-dimethoxy-3-oxo-2-(thiophen-2-ylmethylidene)butanoate Chemical compound COC(OC)C(=O)C(C(=O)OC)=CC1=CC=CS1 UWPTXKIEBAMPKY-UHFFFAOYSA-N 0.000 description 1
- PJYQRBMGZRVNSQ-UHFFFAOYSA-N methyl 4,4-dimethoxy-3-oxobutanoate Chemical compound COC(OC)C(=O)CC(=O)OC PJYQRBMGZRVNSQ-UHFFFAOYSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- YCKAGGHNUHZKCL-UHFFFAOYSA-N propan-2-yl 3-aminobut-2-enoate Chemical compound CC(C)OC(=O)C=C(C)N YCKAGGHNUHZKCL-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000005049 silicon tetrachloride Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
New 2-methyl-dihydropyridines are provided of the formula:
New 2-methyl-dihydropyridines are provided of the formula:
Description
. ~ . , .
'7
'7
2-METHYL-DIHYDROPYRIDINE COMPOUND, PROCESSES
FOR PREPARATION THER~OF AND PHARMACEUTICAL
COMPOSITION COMPRISING THE SAME
This invention relates to 2:-methyl-dihydropyridine :~: compound and a salt thereof. More particularly, it relates to a new~2-methyl-dihydropyridine compound and a pharmaceutically acceptable salt thereo~ which haYe vasodilating and anti-hypertensive activi:ties, to processes for the preparation thereof,:and to a pharmaceutical composition compris~ng the same ~or ` therapeutical trea~men~ of cardiovascular disorder : and hypertension in human being.
With regard to the states of the arts in this ~ield, for example, the following dihydropyridine : ~ ~
~: ~ compounds are known.
:: : ~ ' '~ ~ .
~ , ~ , I~L N02 A-lCH300C~ COQCH3 ~U.S.P. 3,485,847) (Ni fe dip ine ) ~ 2 ~1 A-2 C2H5OOC\ ~ COOCzH5 (German Offenlegungsschrift 26 29 892) ~13 H -\CN
A-3 C~H500C ~ OOC2H5 (Ger29n892)enlegungsschri~t One object of this invention:is to provide the new and useful 2-methyl-dihydropyridine compound and ~, :~ a pharmaceutically acceptable salt thereof, which are structurally characterized in the substituent at the third position of the dihydropyridine nucleus and have stronger activity as compa~ed with the known compounds, for example, as shown above, : Another object of this in~ention is to provide processes for the preparation of said 2-methyl-dihydropyridine compound and the salt thereof.
~: 35 A furtber object of this invention lS to pro~ide ~ .
::
FOR PREPARATION THER~OF AND PHARMACEUTICAL
COMPOSITION COMPRISING THE SAME
This invention relates to 2:-methyl-dihydropyridine :~: compound and a salt thereof. More particularly, it relates to a new~2-methyl-dihydropyridine compound and a pharmaceutically acceptable salt thereo~ which haYe vasodilating and anti-hypertensive activi:ties, to processes for the preparation thereof,:and to a pharmaceutical composition compris~ng the same ~or ` therapeutical trea~men~ of cardiovascular disorder : and hypertension in human being.
With regard to the states of the arts in this ~ield, for example, the following dihydropyridine : ~ ~
~: ~ compounds are known.
:: : ~ ' '~ ~ .
~ , ~ , I~L N02 A-lCH300C~ COQCH3 ~U.S.P. 3,485,847) (Ni fe dip ine ) ~ 2 ~1 A-2 C2H5OOC\ ~ COOCzH5 (German Offenlegungsschrift 26 29 892) ~13 H -\CN
A-3 C~H500C ~ OOC2H5 (Ger29n892)enlegungsschri~t One object of this invention:is to provide the new and useful 2-methyl-dihydropyridine compound and ~, :~ a pharmaceutically acceptable salt thereof, which are structurally characterized in the substituent at the third position of the dihydropyridine nucleus and have stronger activity as compa~ed with the known compounds, for example, as shown above, : Another object of this in~ention is to provide processes for the preparation of said 2-methyl-dihydropyridine compound and the salt thereof.
~: 35 A furtber object of this invention lS to pro~ide ~ .
::
-3-a useful pharmaceutical composition comprising, as an active ingredient, said 2-methyl dihydropyridine compound or the pharmaceutical:Ly acceptable salt thereof, which is useful, as a vasodilator and anti-hypertensive.agents~
Still ~urther object of this invention is toprovide a therapeutical method for treatment of cardiovascular disorder such as coronary insufficiency~
angina pectoris or myocardial :infarction and hyper-tension.
The 2-methyl-dihydropyridine compound o this invention can be represented by the following formula:
Rl ~ (I) wherein Rl is phenyl, 3-nitrophenyl, 2-chlorophenyl, 2-trifluoromethylphenyl, 2-methoxyphenyl, : ~ 2-allyloxyphenyl, 2,4-dichlorophenyl, 3 9 4-dichlorophenyl, 3,4-dimethoxyphenyl, : 25 2-tolyl, 4-pyridyl or 2-thienyl, : R2 is propyl, isopropyl, 2-chloroethyl, 2-- hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methyl-amino)ethyl, ~:~ 30 R3 is lower alkyl, and R4 is di~lower)alkoxymethyl~ formyl, hydroxy-methyl or cyano, pro~ided that, when Rl is 3-nitrophenyl, ~hen R is 2-hydroxyethyl and R is cyano or formyl, or R is propyl or isopropyl.
With regard to ~he object compound o the above formula (I), it is to be undeTstood that theTe can 5 be a pair of two optical isomers due to the asymmetric carbon atom at the ~ourth pos:ition o the dihydro-pyridine nucleus; and accordingly, this type of isomers are to be included within the scope of this invention and r~presented by the same formula (I), inclusively~
According to this invent:ion, the object compound (I) can be prepared by the processes as illustrated by the ~ollowing schemes.
[I] Construction o~ ~undamental structure:-(1) Process 1:
Rl Rl~CH=C-C~Ra + CH3-1C=CH CRa~ Ra ~ ooR3 (II-l) (m -1) (I-l') wherein Rl and R3 are each as defined befoTe, R2 is propyl9 isopropyl, 2-chlo~oethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyl-oxyethyl or 2- (N-benzyl-N-methylamino) -
Still ~urther object of this invention is toprovide a therapeutical method for treatment of cardiovascular disorder such as coronary insufficiency~
angina pectoris or myocardial :infarction and hyper-tension.
The 2-methyl-dihydropyridine compound o this invention can be represented by the following formula:
Rl ~ (I) wherein Rl is phenyl, 3-nitrophenyl, 2-chlorophenyl, 2-trifluoromethylphenyl, 2-methoxyphenyl, : ~ 2-allyloxyphenyl, 2,4-dichlorophenyl, 3 9 4-dichlorophenyl, 3,4-dimethoxyphenyl, : 25 2-tolyl, 4-pyridyl or 2-thienyl, : R2 is propyl, isopropyl, 2-chloroethyl, 2-- hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methyl-amino)ethyl, ~:~ 30 R3 is lower alkyl, and R4 is di~lower)alkoxymethyl~ formyl, hydroxy-methyl or cyano, pro~ided that, when Rl is 3-nitrophenyl, ~hen R is 2-hydroxyethyl and R is cyano or formyl, or R is propyl or isopropyl.
With regard to ~he object compound o the above formula (I), it is to be undeTstood that theTe can 5 be a pair of two optical isomers due to the asymmetric carbon atom at the ~ourth pos:ition o the dihydro-pyridine nucleus; and accordingly, this type of isomers are to be included within the scope of this invention and r~presented by the same formula (I), inclusively~
According to this invent:ion, the object compound (I) can be prepared by the processes as illustrated by the ~ollowing schemes.
[I] Construction o~ ~undamental structure:-(1) Process 1:
Rl Rl~CH=C-C~Ra + CH3-1C=CH CRa~ Ra ~ ooR3 (II-l) (m -1) (I-l') wherein Rl and R3 are each as defined befoTe, R2 is propyl9 isopropyl, 2-chlo~oethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyl-oxyethyl or 2- (N-benzyl-N-methylamino) -
4 ethyl ana : Ra is di(lowe~)alkoxymethyl, : ~ provided that - when R' is 3-nitrophenyl, : ~ then R2 is propyl or is opropyl .
(2) Process 2 Rl Rl-CH=C-COCH3 ~ R4-C=CH-CoOR3~R2OOC~:ooR3 ~OORa ~H2 CH ~ ~ 4 3S (~ -2) ~m -2) 3 H a (I-2) :
~ .
'7 -s-wherein Rl, R2, R3 and R4 are each as defined before, provided that, when Rl is 3-nitrophenyl, then Ra is propyl or isopropy:l.
[II~ Transformations of a f~lctional group:-~3) Process 3-R2OOC ~ ~ CooR3 Hydrolysis R2OOC ~ CoOR3 (I-l) (I-3) wherein Rl, R2) R3 and R4a are each as defined beforQ, provided that, when Rl is 3-nitrophenyl, then R2 is propyl, isopropyl or 2-`hydroxyethyl.
~4) Process 4:
.
Rl' Rl `
: R2OOC ~ CoOR3 ReductionR2OOC ~ CoOR3 , ~I-3) ~I-4) wherein Rl, R2 and R3 are each as defined before, provided that, when Rl is 3-nitrophenyl, then R is propyl or isopropyl.
3a ~5) Process 5:
Rl ~i) Hydroxylamine Rl RbOOC ~ CoOR3 or a salt thereof RbOOC ~ CoOR3 ~ N ~) ~hydrating t CH 3 H CHO agent CH ~ 'CN
~I-3') (I-S~
wherein Rl and R3 are each as defined before, and Rb is propyl, isopropyl, 2-hydroxyethyl, Z~ethoxyethyl, Z-phenoxyethyl, 2-benzyloxy-ethyl or 2-(N-benzyl-N-methylamino)ethyl, provided that, when Rl is 3-nitrophenyl, then Rb is propyl, isopropyl or 2-hydroxyethyl.
~6) Process 6:
._ Rl Rl Re20CH2CH200C~COOR HydTOlysi5 HOCH2~H200C~cooR3 . CH3 H CN 3 H
~IIc) ~I-6) . wneréin Rl and R3 are each as defined before, and Re is acyl.
) ProCess-?
~1 ~;~ ClC~z~HzOOC ~ C6H5CHz S ~ CH2CH ~ ~ COC 3 : ~ 35 ~ IId~ 7) '' , .
7~
, wh-~re~n Rl, R3 and R4 are each as defined before, provided that, when Rl is 3-nitrophenyl) then R is propyl OT isopropyl.
, .
"Lower alkylt' for R3 includes Cl-C6alkyl, pre-ferably Cl-C3alkyl and more preferably normal straight ones such as methyl, ethyl, propyl or the like.
"Di(lower)alkoxymethyl" ~or R4 and Ra includes di(Cl-C6 straight and branchecl chain lower alkoxy)-methyl, preferably Cl-C3 ones such as dimethoxymethyl, diethoxyme~hyl, dipropoxymethyl or the like.
"Acyl" for Re includes a conventional one, pre-ferably alkanoyl, and more preferably lower alkanoyl such as Cl-C6alkanoyl (e.g. formyl, acetyl, propiollyl~
butyryl, isobutyryl, valeryl, etc.~, or the like.
The starting compounds (II-l) and ~ 2) used in Processes 1 and 2 include new and known ones and new ones can be prepared by reacting 4-substituted aceto-acetate (IIA) or (IIA') and aldehyde (IIB) as shown inthe following reaction schemes according to a conven-tional manner.
) R~ 10 + R4-CoCH;~CooR3--,~ Rl-CH=C-CO-Ra 2~
COOR
wherein Rl, R3 and R4 are each as defined before.
~) Rl-CHO + CH3COCHzCOOR2 `-- > Rl-CH=C-COCH3 :~ ~OORa ) (IIAI) (II-2) wherein Rl and R2 are each as defined before.
~`~ a ~ ' . ., ~ .
1~7~:~'7 The other starting compounds (III-l) and ~III-2) used in Processes 1 and 2 can be prepared from a 4-substituted acetoacetate compound (IIIA) or ~IIIA') and ammonia or a salt thereof as shown in the following reaction schemes.
3-~-CH2CRa + NH3 --~ CH3-C=CH-COORa (IIIA) (III-l) wherein Ra is as defined before.
~ Ra-S-CH2CooR3 ~ NH3 __~ Ra- ~ CH-CooR3 ~IIIA'~ (III-2) 2~ wherein R3 and R4 are each as defined before.
a Fur~her, the starting compound (IIC) used in Process 6 can be pTepared by the method as shown in the following reaction scheme, and the compound (I-8) 2~ can be prepared according to the similar manner to ~, those of Process 2 and ~ollowed by the Process 3 as :~ . mentioned above.
Rl (i) Hyd~oxyl~ne Rl HOaH2CH200C I ~ R3hydrochlri~ R2.0CH2CH200C ~ ~ R3 30 C~31N~O e 2 CH3~NJlCN
H H
(I-8) (IIc) wherein Rl, R3 and Re a~ each aS ~fmed before.
..
. . .
Processes for preparation of the 2-methyl-dihydropyrldine compound ~I) will be explained in details below.
~1) Process 1 This process relates to a method for pre-paring a compound tI-l') by reacting a compound (II-l) with an amino compound (III-l).
Each of the starting compounds ~II-l) and (III-l) includes cis and trans geometrical isomers due to the double bond in their molecules, and according to this process, the compound (I-ll) can be prepared by any sequence of the reaction of either geometrical isomers of compound _- 15 (II-l) with either on0s of the compound (III-l), and accordingly all isomers and optional mixtures of the isomers of these starting compounds tII-l) and (III-l) are to be included within the scope of this process.
The reaction can be carried oùt at ambient temperature or under warming or heating. The re-action can preferably be conducted in the absence of a solvent, but may be conducted in a suitable solvent such as benzene, toluene, xylene, chloroform, ;~5 carbon tetrachloride, methylene chloride, ethylene .
chloride, or other conventional solvents. The re-action can preferably~be accelerated in the pre-sence of an agent such as an acid (e.g. acetic acid), a base (e~.g. pyridine or picoline) or in a conven-tional buffer solution. These agents act as a reac-tion accelerator and may also be used as a solvent in case that they~are in liquid. The reaction can also be accelerated by warming or heating. The reaction condition may vary according to the kind of the reactants, solvent and/or other agent as mentioned above to be used -As to the reaction mode of this Process, it .
'3L7 ....
is to be noted that it can alternatively be conducted, for example, by reacting the 4-substitu~0d acetoacetate compound (IIA~, with the aldehyde (IIB) in the presence of the amino compound (III-l).
(2) Process 2:
This process relates to a method for pre-paring a compound (I-2) by reacting a compound (II-Z) with an amino compound (III-2).
This process is substantially the same as Process 1, and accordingly can be conducted by reacting the compound (II-2) with (III-2) in the same manner as those for the Proc~ss 1. That is, the same reaction conditions (e.g. reaction tem-perature, solvent, accelerator, etc.) and the same alternative reac~ion procedure as mentioned in the Process 1 are also applied to this process, provided that the compound (II-2) or alternative reactànts (IIA') and ~IIB), and the compound (III-2) are used in ~his process instead of using the compound ~II-l) or alternative reactants (IIA) and ~IIB), and th~ compound (III-l) in the Process 1, respectirely.
(3) Process 3: ~, This process relates to a me~hod for pre-paring a compound (I-3) by hydrolysing a compound The compound (I-l} can be prepared by the method as illustrated in the above (Processes 1 and ~).
In this process, the di~lower)alkoxymethyl group for Ra of the compound (I 1~ is ~ransforme~
into a formyl group.
Hydrolysis may be carried out in a conven-tional m~ner which is applicable to cleavage F
-.~ .
~ 7 so~called acetal function into the correspond-ing carbonyl ~unctionJ and preferably, for example, an acidic hydrolysis, i.e. in the presence of an acid such as an inorganic acid (e.g. hydrochloric acid, sulfuric acid, etc.) or an o~ganic acid ~e~g~ formic acid, acetic acid, trifluoroacetic acid, p-toluenesulonic acid, etc.), or an acidic ion-exchange resin.
This hydrolysis may be carried out in a sui~able conventional solvent such as water, acetone, methyl ethyl ketone, dioxane, ethanol, methanol, N,N-dimethylformamide, or dimethyl-suloxide, an optional mixture thereof or a buffer solution thereof. The reaction tempe-rature is not restrictive, and the reaction is usually conducted under cooling, at room tem-perature or under somewhat elevated temperature.
(4) Process 4:
This process relates to a method for pre-~0 paring a compound (I-4) by reducing the compound ~I-3).
;~; The reduction can be carried out in a con-ventianal manner which can be~ applied to reduction of a formyl group into a hydroxymethyl : 25 group ,: and particularly, ~he reduction is con-ducted by using a reducing agent such as an alkali metal borohydride ~e.g;. lithium borohydride, sodium borohydride, potassium borohydTide, sodium cyanoborohydride, etc.) or by catalytic reduction for which preferable catalyst may be palladium carbon, palladium chloride OT rhodium carbon and he like. The reduction is usually carried out in a conven~ional solvent such as water, methanol, ethanol, isopropanol, dimethylformamide, tetra-hydTofuran, etc., and *he like. The ~eaction ' ~7 ~7 temperature is not restrictive J and the react-ion is usually carried out undar cooling, at room temperature or at somewhat eleva~ed tem-perature. And, the method of reduction may optionally be selected according to the kind of the compound (I-3).
(2) Process 2 Rl Rl-CH=C-COCH3 ~ R4-C=CH-CoOR3~R2OOC~:ooR3 ~OORa ~H2 CH ~ ~ 4 3S (~ -2) ~m -2) 3 H a (I-2) :
~ .
'7 -s-wherein Rl, R2, R3 and R4 are each as defined before, provided that, when Rl is 3-nitrophenyl, then Ra is propyl or isopropy:l.
[II~ Transformations of a f~lctional group:-~3) Process 3-R2OOC ~ ~ CooR3 Hydrolysis R2OOC ~ CoOR3 (I-l) (I-3) wherein Rl, R2) R3 and R4a are each as defined beforQ, provided that, when Rl is 3-nitrophenyl, then R2 is propyl, isopropyl or 2-`hydroxyethyl.
~4) Process 4:
.
Rl' Rl `
: R2OOC ~ CoOR3 ReductionR2OOC ~ CoOR3 , ~I-3) ~I-4) wherein Rl, R2 and R3 are each as defined before, provided that, when Rl is 3-nitrophenyl, then R is propyl or isopropyl.
3a ~5) Process 5:
Rl ~i) Hydroxylamine Rl RbOOC ~ CoOR3 or a salt thereof RbOOC ~ CoOR3 ~ N ~) ~hydrating t CH 3 H CHO agent CH ~ 'CN
~I-3') (I-S~
wherein Rl and R3 are each as defined before, and Rb is propyl, isopropyl, 2-hydroxyethyl, Z~ethoxyethyl, Z-phenoxyethyl, 2-benzyloxy-ethyl or 2-(N-benzyl-N-methylamino)ethyl, provided that, when Rl is 3-nitrophenyl, then Rb is propyl, isopropyl or 2-hydroxyethyl.
~6) Process 6:
._ Rl Rl Re20CH2CH200C~COOR HydTOlysi5 HOCH2~H200C~cooR3 . CH3 H CN 3 H
~IIc) ~I-6) . wneréin Rl and R3 are each as defined before, and Re is acyl.
) ProCess-?
~1 ~;~ ClC~z~HzOOC ~ C6H5CHz S ~ CH2CH ~ ~ COC 3 : ~ 35 ~ IId~ 7) '' , .
7~
, wh-~re~n Rl, R3 and R4 are each as defined before, provided that, when Rl is 3-nitrophenyl) then R is propyl OT isopropyl.
, .
"Lower alkylt' for R3 includes Cl-C6alkyl, pre-ferably Cl-C3alkyl and more preferably normal straight ones such as methyl, ethyl, propyl or the like.
"Di(lower)alkoxymethyl" ~or R4 and Ra includes di(Cl-C6 straight and branchecl chain lower alkoxy)-methyl, preferably Cl-C3 ones such as dimethoxymethyl, diethoxyme~hyl, dipropoxymethyl or the like.
"Acyl" for Re includes a conventional one, pre-ferably alkanoyl, and more preferably lower alkanoyl such as Cl-C6alkanoyl (e.g. formyl, acetyl, propiollyl~
butyryl, isobutyryl, valeryl, etc.~, or the like.
The starting compounds (II-l) and ~ 2) used in Processes 1 and 2 include new and known ones and new ones can be prepared by reacting 4-substituted aceto-acetate (IIA) or (IIA') and aldehyde (IIB) as shown inthe following reaction schemes according to a conven-tional manner.
) R~ 10 + R4-CoCH;~CooR3--,~ Rl-CH=C-CO-Ra 2~
COOR
wherein Rl, R3 and R4 are each as defined before.
~) Rl-CHO + CH3COCHzCOOR2 `-- > Rl-CH=C-COCH3 :~ ~OORa ) (IIAI) (II-2) wherein Rl and R2 are each as defined before.
~`~ a ~ ' . ., ~ .
1~7~:~'7 The other starting compounds (III-l) and ~III-2) used in Processes 1 and 2 can be prepared from a 4-substituted acetoacetate compound (IIIA) or ~IIIA') and ammonia or a salt thereof as shown in the following reaction schemes.
3-~-CH2CRa + NH3 --~ CH3-C=CH-COORa (IIIA) (III-l) wherein Ra is as defined before.
~ Ra-S-CH2CooR3 ~ NH3 __~ Ra- ~ CH-CooR3 ~IIIA'~ (III-2) 2~ wherein R3 and R4 are each as defined before.
a Fur~her, the starting compound (IIC) used in Process 6 can be pTepared by the method as shown in the following reaction scheme, and the compound (I-8) 2~ can be prepared according to the similar manner to ~, those of Process 2 and ~ollowed by the Process 3 as :~ . mentioned above.
Rl (i) Hyd~oxyl~ne Rl HOaH2CH200C I ~ R3hydrochlri~ R2.0CH2CH200C ~ ~ R3 30 C~31N~O e 2 CH3~NJlCN
H H
(I-8) (IIc) wherein Rl, R3 and Re a~ each aS ~fmed before.
..
. . .
Processes for preparation of the 2-methyl-dihydropyrldine compound ~I) will be explained in details below.
~1) Process 1 This process relates to a method for pre-paring a compound tI-l') by reacting a compound (II-l) with an amino compound (III-l).
Each of the starting compounds ~II-l) and (III-l) includes cis and trans geometrical isomers due to the double bond in their molecules, and according to this process, the compound (I-ll) can be prepared by any sequence of the reaction of either geometrical isomers of compound _- 15 (II-l) with either on0s of the compound (III-l), and accordingly all isomers and optional mixtures of the isomers of these starting compounds tII-l) and (III-l) are to be included within the scope of this process.
The reaction can be carried oùt at ambient temperature or under warming or heating. The re-action can preferably be conducted in the absence of a solvent, but may be conducted in a suitable solvent such as benzene, toluene, xylene, chloroform, ;~5 carbon tetrachloride, methylene chloride, ethylene .
chloride, or other conventional solvents. The re-action can preferably~be accelerated in the pre-sence of an agent such as an acid (e.g. acetic acid), a base (e~.g. pyridine or picoline) or in a conven-tional buffer solution. These agents act as a reac-tion accelerator and may also be used as a solvent in case that they~are in liquid. The reaction can also be accelerated by warming or heating. The reaction condition may vary according to the kind of the reactants, solvent and/or other agent as mentioned above to be used -As to the reaction mode of this Process, it .
'3L7 ....
is to be noted that it can alternatively be conducted, for example, by reacting the 4-substitu~0d acetoacetate compound (IIA~, with the aldehyde (IIB) in the presence of the amino compound (III-l).
(2) Process 2:
This process relates to a method for pre-paring a compound (I-2) by reacting a compound (II-Z) with an amino compound (III-2).
This process is substantially the same as Process 1, and accordingly can be conducted by reacting the compound (II-2) with (III-2) in the same manner as those for the Proc~ss 1. That is, the same reaction conditions (e.g. reaction tem-perature, solvent, accelerator, etc.) and the same alternative reac~ion procedure as mentioned in the Process 1 are also applied to this process, provided that the compound (II-2) or alternative reactànts (IIA') and ~IIB), and the compound (III-2) are used in ~his process instead of using the compound ~II-l) or alternative reactants (IIA) and ~IIB), and th~ compound (III-l) in the Process 1, respectirely.
(3) Process 3: ~, This process relates to a me~hod for pre-paring a compound (I-3) by hydrolysing a compound The compound (I-l} can be prepared by the method as illustrated in the above (Processes 1 and ~).
In this process, the di~lower)alkoxymethyl group for Ra of the compound (I 1~ is ~ransforme~
into a formyl group.
Hydrolysis may be carried out in a conven-tional m~ner which is applicable to cleavage F
-.~ .
~ 7 so~called acetal function into the correspond-ing carbonyl ~unctionJ and preferably, for example, an acidic hydrolysis, i.e. in the presence of an acid such as an inorganic acid (e.g. hydrochloric acid, sulfuric acid, etc.) or an o~ganic acid ~e~g~ formic acid, acetic acid, trifluoroacetic acid, p-toluenesulonic acid, etc.), or an acidic ion-exchange resin.
This hydrolysis may be carried out in a sui~able conventional solvent such as water, acetone, methyl ethyl ketone, dioxane, ethanol, methanol, N,N-dimethylformamide, or dimethyl-suloxide, an optional mixture thereof or a buffer solution thereof. The reaction tempe-rature is not restrictive, and the reaction is usually conducted under cooling, at room tem-perature or under somewhat elevated temperature.
(4) Process 4:
This process relates to a method for pre-~0 paring a compound (I-4) by reducing the compound ~I-3).
;~; The reduction can be carried out in a con-ventianal manner which can be~ applied to reduction of a formyl group into a hydroxymethyl : 25 group ,: and particularly, ~he reduction is con-ducted by using a reducing agent such as an alkali metal borohydride ~e.g;. lithium borohydride, sodium borohydride, potassium borohydTide, sodium cyanoborohydride, etc.) or by catalytic reduction for which preferable catalyst may be palladium carbon, palladium chloride OT rhodium carbon and he like. The reduction is usually carried out in a conven~ional solvent such as water, methanol, ethanol, isopropanol, dimethylformamide, tetra-hydTofuran, etc., and *he like. The ~eaction ' ~7 ~7 temperature is not restrictive J and the react-ion is usually carried out undar cooling, at room temperature or at somewhat eleva~ed tem-perature. And, the method of reduction may optionally be selected according to the kind of the compound (I-3).
(5) Process 5:
This process relates to a me~hod ~or pre-paring a compound (I 5) by reacting a compound ~I-3') with hydroxylamine or a salt thereof, and then reacting the res.ultant product with a dehydrating agent.
According to this process, the formyl group of the starting compound (I-3') may be transformed into the hydroxyiminomethyl group (the first step~, and in succession said group is transformed into the cyano group (the second step).
Preferable salt o hydroxylamine may be a salt with an acid such as an inorganic acid (e.g.
hydrochloric acid, sulfuric acid, etc.) or an organic acid (e.g. acetic acid, etc.).
(i) The irst step:-The reaction of this step is carried out in a usual manner as so-called oximation ~eaction, for ~ ~ 25 example, in the presencs of an acid (e.g. hydTochloric `~ acid, hydrobromic acid, sulfuric~acid, formic acid, acetic acid, p-toluenesulonic acid, boron trifluoride, silicon tetrachloride or ~itanium tetrachloride); in a basic condition brought abou~ by a base, for example free hydroxylamine; or in an acidic or basic conven-tional buffer s~olution. The reaction is usually con-ducted in a suitable conventional solvent such as water, dioxane, ethanol, methanol, dimethylformamide or an optional mixture thereof, and in case that the above acid is in li.quid, it can also be used as a solvent.
~::
7~7 The reaction temperature is not restrictive, and the reaction is usually carried out under cooling, at room temperature or under somewhat elevated tem-perature The reaction product of the ~irst step is subjected to the ollowing second step with or without isolation and/or p~rification.
~ii) The second step:-Suitable dehydrating agent used in this step includes conventional organic or inorganic ones such as inorgani~ acid (e.g. sulfuric acid, phosphoric acid, polyphosphoric acid, etc.), an organic acid (e.g. formic acid, ^ 15 acetic acid, trifluoroacetic acid, ethanesul~onic . .
acid, p-toluenesulfonic acid, etc.), an organic acid anhydride (e.g acetic anhydride, benzoic anhydride, phthalic anhydride, etc.), an organic acid halide (e.g. acetyl chloride, benzoyl chloride, trichloro-acetyl chloride, mesyl chloride, tosyl chloride, ethyl chloroformate, phenylchlorofoTmate, etc.);
an inorganic halogen compound (e.g. thionyl chloride, phosphorus pentachloride, phosphorus oxychloride, phosphorus tribromide, stannic chloride, titanium tetrachloride, etc.); a carbodiimide ~e.g. N,N'- ., dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholino-ethylcarbodiimide, etc.), N,N'-carbonyldiimidazole, pentamethyleneketene-N-cyclohexylimine; ethoxyacetylene;
2-ethyl-7-hydroxyisoxazolium salt; other phosphorus compound (e.g. phosphorus pentoxide, polyphosphoric acid ethyl ester, triethylphosphate or phenylphosphate) and the like or an optional mixture thereof. When an acid is used as the dehydrating agent~ the reaction can also be conducted in the presence of its salt such as an alkali metal salt (e.g. sodium salt or potassium salt), or the like.
, '7 14~
This reaction is usually carried out in a conventional solvent such as diethyl ether, dimethylformamide, pyridine, acetic acid, ~ormic acid, benzene, carbon tetrachLoride, chloroform, methylene chloride, tetrahydrofuran, dioxane, and the like, and usually carried out at room temperature OT under heating, but the reac~ion ~emperature is not restrictive to the above.
~6~ Process 6:
This process relates to a method for preparing a compound ~I-6) by hydrolysing a compound (IIc).
In this process, the acyl group for Re f the compound ~IIc) is eliminated by hydrolysis to give the 2-hydroxyethyl compound (I-6).
Hydrolysis is carried out in a con~entional manner which is conventionally applied to a cleavage of a so-called ester bond into the hydroxy function, and is preferably carried out 9 for example, by a basic hydrolysis, i.e. in the presence of a base such as an alkali metal hydroxide, carbonate or bicarbonate, ~e.g. sodium hydroxide, potassium hydroxideJ sodium carbonate, potassium carbonate, sodium bicarbonate, etc.~ or by an acidic hyarolysis in the presence of an organic or inorganic acid, suitable examples thereof include those given in the above-mentioned Process 3.
This hydrolysis may preferably be caTried out in a conventional solvent such as water, acetone, dioxane, me~hanol, e~hanol, dimethylfoTmamide~
dime*hylsulfoxide, or an optional mixture thereof.
The reaction temperature is not restrictive, and the reaction is usually conducted at room temperature or under heating.
t7) Process 7:
This process relates to a method for pre-paring a compound ~I-7) by reacting a compound ~IID) with N-methyl benzylamine.
The reaction is usually carried out in a suitable solvent such as chloroform, methylene chloride,benzene, acetone, diethyl ether, tetrahydrofuran, dimethylformamide, methanol, ethanol~propanol, isopropanol,water and other conventional solvent or an optional mixture ~hereof.
This reaction can also be carried out in the presence of a base, suitable examples of which include an inorganic base such as an alkali metal hydroxide, carbonate bicar-bonate, hydride or amide (e.g. sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, sodium hydride, sodium amide, etc.) or an organic base such as an alkali metal alkoxide (e.g. sodium methoxide, sodium ethoxide, potassium ethoxide, lithium methoxide, etc.), a salt of an organic acid (e.g. sodium acetate, potassium acetate, etc.), a tertiary amine or imine base (e.g. trie~hylamine, pyridine, picoline, N,N-dime~hylaniline, N-methylpyrolidine,N-methylmorpholine, etc~) and the like.
Furthar, this reac~ion is preferably carried out in the presence of an alkali metal iodide such as lithium iodidQ, sodium iodide or the like in addition ~o the base.
The reaction temperature is not restrictive, and the reaction is usually carried ou~ at room temperature, or under warming or hea~ing.
According to this invention, the object reaction product can be separated and isolated from the reaction mixture and purified by methods commonly used for this purpose, for instance, extraction with suitable sol~ent, chromatography, precipitation, recrystalliæation and so on.
Suitable examples of a salt of the ~9 7 ~ ~'7 ;~`
2-methyl-dihydropyridine compound ~I) include a pharmaceutically aoceptable salt such as an inorganic acid salt (e.g. hydrochloride, hydrobromide, phosphate, sulfate, etc.) and an organic acid salt (e.g. ~ormate, acetate J fumara~e, maleate, aspartate, glutamate, etc.).
The compound (I) thus obtained frequently includes at leas~ one pair of optical isomers due to the presencP of an asymmetric carbon atom of the fourth position of the 1,4-dihydropyridine nucleus and can exist as each optical isomer or a mixture thereof.
A racemic compound can be resolved into each optlcal isomer by a conven~ional method for racemic resolution, such as a chemical resolution of the salts of the diastereomer with a conventional optically active acid te.g. tartaric acid or camphor sulfonic acid, etc.).
It is to be noted that the compound tI) and a pharmaceutically acceptable salt thereo~ possess a strong vasodilating and anti-hypertensive activities and useful for therapeu~ical treatment in cardiovascular disorder and hypertension such as coronary insufficiency, angina pectoris or myocardial infarction, and hyperten-sion.
Particularly, the strong pharmacological activi~ies of ~he compound (I) according to this inven- ~, tion is structurally characterized by the radical R2, specifically selected rom the group consisting of propyl, isopropyl, 2-chloroe~hyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl and 2-~N-benzyl-N-methylamino)ethyl.
More particularly, the compound (I), wherein3 for example, i) Rl is 3-nitrophenyl or 2-chlorophenyl, R2 is isopropyl, R3 is methyl and R4 is cyano, and-ii) Rl is 2-trifluoromethylphenyl, R is isopropyl or 2-phenoxyethyl, R3 is methyl and R4 is hydroxymethyl .
.
.
. . , ~
.
1~7~
or cyano, possesses stronger therapeutical ef~ects as mentioned abo~e, as compared with -the known compound as mentioned hereinbefore.
Further, the compound (I), wherein, or example, iii) Rl is 3-nitrophenyl or 2-chlorophenyl, R2 is isopropyl, R3 is methyl and R4 is dimethoxymethyl or formyl, and i~) Rl is 2-trifluoromethylphenyl, R2 is isopropyl or 2-phenoxyethyl, R3 is methyl or ethyl and R is dimethoxymethyl, diethoxymethyl or formyl, is useful not only as vasodilating and anti-hypertensive agents but also as an intermediate ~or preparing the more preferable vasodilating and anti-hypertensive agents of this invention as illustrated hereinabove.
For therapeutical purpose 9 the 2-methyl-dihydropyridine compound (I) is administered in daily dose of 0.1 to 500 mg3 preferably 1 to 50 mg.
The pharmaceutical compositions of this invention comprise, as an active ingredient, the 2-methyl-dihydropyridine compound (I) or pharmaceuti-cally acceptable salt thereof in an amount of about 0.01 mg. to about 500 mg., preferabIy about 0.1 mg.
to about 250 mg. per dosage unit for oral and paren-teral use. ~' One skilled in the ar~ will recognize that the amount-of the active ingredient in the dosage unit form may be determined by considering the activity of the ingredient as well as the size of the host human being. The active ingredient may usually be formulaked in a solid form such as tablet, granule, powder, capsule, troche, lozenge or suppo-~- sitory, or a suspension or solution form such as syrup, injection, emulsion, lemonade, etc and ~he like.
A pharmaceutical carrier or diluent includes solid or '' . ., ' ~ .
: ~ ~
73L~'7 liquid non-toxic pharmaceutically acceptable sub-stances. Examples of solid or liquid carriers or diluents are lactose, magnesium stearate; terra alba, sucrose, corn starch, talc, stearic acid, gelatin, agar, pectin, acacia, peanut oil, olive oil or sesame oil, cacao butter, ethyleneglycol or the other conventional ones. Similarly, the carrier or diluent may include a time delay material such as glyceryl monostearate, glyceryl distearat~, a wax and the like.
~or the purpose of showing the utility of the compound [I), the pharmacological test results o~
some represented compounds will be shown as follows.
HYpotensive effect:
Test Method;
Five Wistar rats were used per group. Each animal was immobilized in a cage sized to the body. Blood pre-ssure was measured at the femoral artery by means o a pressure transducer and recorded as electrically integrated values of mean arterial pressure, and heart rate was determined by a pulse wave detector.
Opera~ion for the catheterization was performed under light ~nesthesia with ether. The test compound was administered orally 3 hours after completion of the operation.
Test Compound;
Compound A-l : Nifedipine (reference compound) Compound B : Isopropyl ester o 6-cyano-5-methoxy-carbonyl-2-methyl-4-t3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.
Compound C : Isopropyl ester of 4-(2-chlorophenyl)- `
This process relates to a me~hod ~or pre-paring a compound (I 5) by reacting a compound ~I-3') with hydroxylamine or a salt thereof, and then reacting the res.ultant product with a dehydrating agent.
According to this process, the formyl group of the starting compound (I-3') may be transformed into the hydroxyiminomethyl group (the first step~, and in succession said group is transformed into the cyano group (the second step).
Preferable salt o hydroxylamine may be a salt with an acid such as an inorganic acid (e.g.
hydrochloric acid, sulfuric acid, etc.) or an organic acid (e.g. acetic acid, etc.).
(i) The irst step:-The reaction of this step is carried out in a usual manner as so-called oximation ~eaction, for ~ ~ 25 example, in the presencs of an acid (e.g. hydTochloric `~ acid, hydrobromic acid, sulfuric~acid, formic acid, acetic acid, p-toluenesulonic acid, boron trifluoride, silicon tetrachloride or ~itanium tetrachloride); in a basic condition brought abou~ by a base, for example free hydroxylamine; or in an acidic or basic conven-tional buffer s~olution. The reaction is usually con-ducted in a suitable conventional solvent such as water, dioxane, ethanol, methanol, dimethylformamide or an optional mixture thereof, and in case that the above acid is in li.quid, it can also be used as a solvent.
~::
7~7 The reaction temperature is not restrictive, and the reaction is usually carried out under cooling, at room temperature or under somewhat elevated tem-perature The reaction product of the ~irst step is subjected to the ollowing second step with or without isolation and/or p~rification.
~ii) The second step:-Suitable dehydrating agent used in this step includes conventional organic or inorganic ones such as inorgani~ acid (e.g. sulfuric acid, phosphoric acid, polyphosphoric acid, etc.), an organic acid (e.g. formic acid, ^ 15 acetic acid, trifluoroacetic acid, ethanesul~onic . .
acid, p-toluenesulfonic acid, etc.), an organic acid anhydride (e.g acetic anhydride, benzoic anhydride, phthalic anhydride, etc.), an organic acid halide (e.g. acetyl chloride, benzoyl chloride, trichloro-acetyl chloride, mesyl chloride, tosyl chloride, ethyl chloroformate, phenylchlorofoTmate, etc.);
an inorganic halogen compound (e.g. thionyl chloride, phosphorus pentachloride, phosphorus oxychloride, phosphorus tribromide, stannic chloride, titanium tetrachloride, etc.); a carbodiimide ~e.g. N,N'- ., dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholino-ethylcarbodiimide, etc.), N,N'-carbonyldiimidazole, pentamethyleneketene-N-cyclohexylimine; ethoxyacetylene;
2-ethyl-7-hydroxyisoxazolium salt; other phosphorus compound (e.g. phosphorus pentoxide, polyphosphoric acid ethyl ester, triethylphosphate or phenylphosphate) and the like or an optional mixture thereof. When an acid is used as the dehydrating agent~ the reaction can also be conducted in the presence of its salt such as an alkali metal salt (e.g. sodium salt or potassium salt), or the like.
, '7 14~
This reaction is usually carried out in a conventional solvent such as diethyl ether, dimethylformamide, pyridine, acetic acid, ~ormic acid, benzene, carbon tetrachLoride, chloroform, methylene chloride, tetrahydrofuran, dioxane, and the like, and usually carried out at room temperature OT under heating, but the reac~ion ~emperature is not restrictive to the above.
~6~ Process 6:
This process relates to a method for preparing a compound ~I-6) by hydrolysing a compound (IIc).
In this process, the acyl group for Re f the compound ~IIc) is eliminated by hydrolysis to give the 2-hydroxyethyl compound (I-6).
Hydrolysis is carried out in a con~entional manner which is conventionally applied to a cleavage of a so-called ester bond into the hydroxy function, and is preferably carried out 9 for example, by a basic hydrolysis, i.e. in the presence of a base such as an alkali metal hydroxide, carbonate or bicarbonate, ~e.g. sodium hydroxide, potassium hydroxideJ sodium carbonate, potassium carbonate, sodium bicarbonate, etc.~ or by an acidic hyarolysis in the presence of an organic or inorganic acid, suitable examples thereof include those given in the above-mentioned Process 3.
This hydrolysis may preferably be caTried out in a conventional solvent such as water, acetone, dioxane, me~hanol, e~hanol, dimethylfoTmamide~
dime*hylsulfoxide, or an optional mixture thereof.
The reaction temperature is not restrictive, and the reaction is usually conducted at room temperature or under heating.
t7) Process 7:
This process relates to a method for pre-paring a compound ~I-7) by reacting a compound ~IID) with N-methyl benzylamine.
The reaction is usually carried out in a suitable solvent such as chloroform, methylene chloride,benzene, acetone, diethyl ether, tetrahydrofuran, dimethylformamide, methanol, ethanol~propanol, isopropanol,water and other conventional solvent or an optional mixture ~hereof.
This reaction can also be carried out in the presence of a base, suitable examples of which include an inorganic base such as an alkali metal hydroxide, carbonate bicar-bonate, hydride or amide (e.g. sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, sodium hydride, sodium amide, etc.) or an organic base such as an alkali metal alkoxide (e.g. sodium methoxide, sodium ethoxide, potassium ethoxide, lithium methoxide, etc.), a salt of an organic acid (e.g. sodium acetate, potassium acetate, etc.), a tertiary amine or imine base (e.g. trie~hylamine, pyridine, picoline, N,N-dime~hylaniline, N-methylpyrolidine,N-methylmorpholine, etc~) and the like.
Furthar, this reac~ion is preferably carried out in the presence of an alkali metal iodide such as lithium iodidQ, sodium iodide or the like in addition ~o the base.
The reaction temperature is not restrictive, and the reaction is usually carried ou~ at room temperature, or under warming or hea~ing.
According to this invention, the object reaction product can be separated and isolated from the reaction mixture and purified by methods commonly used for this purpose, for instance, extraction with suitable sol~ent, chromatography, precipitation, recrystalliæation and so on.
Suitable examples of a salt of the ~9 7 ~ ~'7 ;~`
2-methyl-dihydropyridine compound ~I) include a pharmaceutically aoceptable salt such as an inorganic acid salt (e.g. hydrochloride, hydrobromide, phosphate, sulfate, etc.) and an organic acid salt (e.g. ~ormate, acetate J fumara~e, maleate, aspartate, glutamate, etc.).
The compound (I) thus obtained frequently includes at leas~ one pair of optical isomers due to the presencP of an asymmetric carbon atom of the fourth position of the 1,4-dihydropyridine nucleus and can exist as each optical isomer or a mixture thereof.
A racemic compound can be resolved into each optlcal isomer by a conven~ional method for racemic resolution, such as a chemical resolution of the salts of the diastereomer with a conventional optically active acid te.g. tartaric acid or camphor sulfonic acid, etc.).
It is to be noted that the compound tI) and a pharmaceutically acceptable salt thereo~ possess a strong vasodilating and anti-hypertensive activities and useful for therapeu~ical treatment in cardiovascular disorder and hypertension such as coronary insufficiency, angina pectoris or myocardial infarction, and hyperten-sion.
Particularly, the strong pharmacological activi~ies of ~he compound (I) according to this inven- ~, tion is structurally characterized by the radical R2, specifically selected rom the group consisting of propyl, isopropyl, 2-chloroe~hyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl and 2-~N-benzyl-N-methylamino)ethyl.
More particularly, the compound (I), wherein3 for example, i) Rl is 3-nitrophenyl or 2-chlorophenyl, R2 is isopropyl, R3 is methyl and R4 is cyano, and-ii) Rl is 2-trifluoromethylphenyl, R is isopropyl or 2-phenoxyethyl, R3 is methyl and R4 is hydroxymethyl .
.
.
. . , ~
.
1~7~
or cyano, possesses stronger therapeutical ef~ects as mentioned abo~e, as compared with -the known compound as mentioned hereinbefore.
Further, the compound (I), wherein, or example, iii) Rl is 3-nitrophenyl or 2-chlorophenyl, R2 is isopropyl, R3 is methyl and R4 is dimethoxymethyl or formyl, and i~) Rl is 2-trifluoromethylphenyl, R2 is isopropyl or 2-phenoxyethyl, R3 is methyl or ethyl and R is dimethoxymethyl, diethoxymethyl or formyl, is useful not only as vasodilating and anti-hypertensive agents but also as an intermediate ~or preparing the more preferable vasodilating and anti-hypertensive agents of this invention as illustrated hereinabove.
For therapeutical purpose 9 the 2-methyl-dihydropyridine compound (I) is administered in daily dose of 0.1 to 500 mg3 preferably 1 to 50 mg.
The pharmaceutical compositions of this invention comprise, as an active ingredient, the 2-methyl-dihydropyridine compound (I) or pharmaceuti-cally acceptable salt thereof in an amount of about 0.01 mg. to about 500 mg., preferabIy about 0.1 mg.
to about 250 mg. per dosage unit for oral and paren-teral use. ~' One skilled in the ar~ will recognize that the amount-of the active ingredient in the dosage unit form may be determined by considering the activity of the ingredient as well as the size of the host human being. The active ingredient may usually be formulaked in a solid form such as tablet, granule, powder, capsule, troche, lozenge or suppo-~- sitory, or a suspension or solution form such as syrup, injection, emulsion, lemonade, etc and ~he like.
A pharmaceutical carrier or diluent includes solid or '' . ., ' ~ .
: ~ ~
73L~'7 liquid non-toxic pharmaceutically acceptable sub-stances. Examples of solid or liquid carriers or diluents are lactose, magnesium stearate; terra alba, sucrose, corn starch, talc, stearic acid, gelatin, agar, pectin, acacia, peanut oil, olive oil or sesame oil, cacao butter, ethyleneglycol or the other conventional ones. Similarly, the carrier or diluent may include a time delay material such as glyceryl monostearate, glyceryl distearat~, a wax and the like.
~or the purpose of showing the utility of the compound [I), the pharmacological test results o~
some represented compounds will be shown as follows.
HYpotensive effect:
Test Method;
Five Wistar rats were used per group. Each animal was immobilized in a cage sized to the body. Blood pre-ssure was measured at the femoral artery by means o a pressure transducer and recorded as electrically integrated values of mean arterial pressure, and heart rate was determined by a pulse wave detector.
Opera~ion for the catheterization was performed under light ~nesthesia with ether. The test compound was administered orally 3 hours after completion of the operation.
Test Compound;
Compound A-l : Nifedipine (reference compound) Compound B : Isopropyl ester o 6-cyano-5-methoxy-carbonyl-2-methyl-4-t3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.
Compound C : Isopropyl ester of 4-(2-chlorophenyl)- `
6 - cyano-5-methoxycarbonyl-2-methyl-1~4-dihydropyridine-3-carboxylic acid.-
7~
.
Compound D : Isopropyl ester o 6-cyano-4-~2-trifluoromethylphenyl)-5-methoxy-carbonyl-2-methyl-l,4-dihydropyridine-3-carboxylic acid.
S , .
Compound E : 2-Phenox~ethyl ester of 6-cyano-4-(.2-tri~luoromethylphenyl)-5-ethoxy-carbonyl-2-methyl-l,4-dihydropyridine-3~carboxylic acid.
Compound F : Isopropyl ester of 4-~2-trifluoromethyl-phenyl~-6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-l,4-dihydropyridine-3-carboxylic acid.
Compound G : 2-Phenoxyethyl ester of 4-(2-trifluoro-methylphenyl)-5-ethoxycarbonyl-6-: hydroxymethyl-2-methyl-l,4-dihydropyridine-3-carboxylic acid.
Test Results;
,~ ~
Mean values of ~ Maximum Decrease of blood pressure mmHg) were shown in the following table.
~, (continued to the next page) ~: ~ 30 -:
, "
.
Tabl_ 1 , \ose ¦1 mg/kg 10 mg/kg S Compound I _ .
A-l -25.6 ~ 1.5 -44.6 + 1.2 ~ . _ ~ , -44.6 ~ 1.7 -5~.0 ~ 1. 3 C -29.2 + 3.0 40.6 + Z,~
_ D -34.6 i o.g 47,4 i 1.3 _ . .
E ~-22.8 + 2.1 -44.2 + 1.5 . ... ~._ .... , _ F -18.0 +1.9 -46.6 ~ 2.1 . . _~ ~
G -13,2 +3,3 -47.8 + 2.4 . ~ _ ~:: --'-"
Effect of Coronary Blood Flow :
~; 25 Test Method:
Mongrel dogs, weighing 8-15 kg, were anesthetized with an intrapectoneal dose of pentobarbital sodium 35 mg/kg. After the thorax was opened under artificial ; 30 respiration, a flow-meter probe was fitted to the left circumflex branch of the coronary artery. The blood pressure was measured in the femoral artery, and the object compound of this invention were injected intravenously. The values at peak blood flow were ; 35 measured.
:
:' ' Test Results;
Table 2. Increase of coronary blood flow (~) The value indicate percentages compared to control.
~~~ose _ ~ugtkg :L O 10 0 Test Compound ~ _ _ _ _ 181 219 The following examples are given for the purpose of illustrating this invention.
(continued to the next page) :; , .
~: 30 : :
:
~ 35 ~ .
Preparation of the starting compounds ~or Processes l and 2 S ~ _.
.
1) To a solution of 3-nitrobenzaldehyde ~7 56 g~
and methyl 4,4-dimethoxyacetoacjetate ~7.93 g~ in dried benzene t30 ml~ were added acetic acid (0.18 g) and piperidine (0.17 g), and the mixture was heated under reflux for 3,5 hours, while azeotropically removing the water formed therefrom.
After adding benzene to the reaction mixture 9 the solution was washed successively with water, diluted aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of sodium chloride, in turn and then dried. Removal o~ the solvent under reduced pressure gave an oily residue ~15.74 g), which was chromatographed ove~ silica gel (470 g) with a mixture of benzene and ethyl acetate ~25:1 by volume as an eluent to give a yellow oil (8.06 g) of methyl 4,4-dime~hoxy-2-~3-nitTobenzylidene)-acetoaceta~e (a mixture of cis and trans isomers).
25N.M.R. ~ppm (CDC~3) : 3.45 (s)} ~6H) 3.48 (s) ~ 3-8~ ~5)} ~3H) 4- (S) }(lH), :~ 3.91 (s) 5.08 (s) 7.2S - 8.4 ~5H, m).
The ~ollowing compounds were obtained in sub-stan~ially the same manner as that of prepaTation 1 .
~; 35 :
, , ' ~ ' ' 2) Methyl 4,4-dimethoxy-2-(2-me~hylbenzylidene)-- acetoacetate ~a mixture of cis and trans isomers), N.M.R. ~ppm (CDC~3) : 2.33 (3M, s), 3.Z3 tS) 3,42 ~s) 3.64 (s)}~3H) 4-53 (s)}~lH), 3.79 (s) 5.04 (5) 6.8-7.4 ~4H, m), 7-97 ts)}(lH) ' 8.09 ts) 3) Methyl 2-(2-chlorobenæyiidine)-4,4-dimethoxy-acetoacetate ~a mixture of cis and trans isomers).
N.M.R. ~ppm (CDC~3) : 3.28 ~s) 3.41 (s) 3,71 ts)}t3H) 4.68 tS) ~lH), 3.81 (s) 5.~ ~s) 7 7,5 ~4H, m), 8-02 (s) }~lH).
.
Compound D : Isopropyl ester o 6-cyano-4-~2-trifluoromethylphenyl)-5-methoxy-carbonyl-2-methyl-l,4-dihydropyridine-3-carboxylic acid.
S , .
Compound E : 2-Phenox~ethyl ester of 6-cyano-4-(.2-tri~luoromethylphenyl)-5-ethoxy-carbonyl-2-methyl-l,4-dihydropyridine-3~carboxylic acid.
Compound F : Isopropyl ester of 4-~2-trifluoromethyl-phenyl~-6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-l,4-dihydropyridine-3-carboxylic acid.
Compound G : 2-Phenoxyethyl ester of 4-(2-trifluoro-methylphenyl)-5-ethoxycarbonyl-6-: hydroxymethyl-2-methyl-l,4-dihydropyridine-3-carboxylic acid.
Test Results;
,~ ~
Mean values of ~ Maximum Decrease of blood pressure mmHg) were shown in the following table.
~, (continued to the next page) ~: ~ 30 -:
, "
.
Tabl_ 1 , \ose ¦1 mg/kg 10 mg/kg S Compound I _ .
A-l -25.6 ~ 1.5 -44.6 + 1.2 ~ . _ ~ , -44.6 ~ 1.7 -5~.0 ~ 1. 3 C -29.2 + 3.0 40.6 + Z,~
_ D -34.6 i o.g 47,4 i 1.3 _ . .
E ~-22.8 + 2.1 -44.2 + 1.5 . ... ~._ .... , _ F -18.0 +1.9 -46.6 ~ 2.1 . . _~ ~
G -13,2 +3,3 -47.8 + 2.4 . ~ _ ~:: --'-"
Effect of Coronary Blood Flow :
~; 25 Test Method:
Mongrel dogs, weighing 8-15 kg, were anesthetized with an intrapectoneal dose of pentobarbital sodium 35 mg/kg. After the thorax was opened under artificial ; 30 respiration, a flow-meter probe was fitted to the left circumflex branch of the coronary artery. The blood pressure was measured in the femoral artery, and the object compound of this invention were injected intravenously. The values at peak blood flow were ; 35 measured.
:
:' ' Test Results;
Table 2. Increase of coronary blood flow (~) The value indicate percentages compared to control.
~~~ose _ ~ugtkg :L O 10 0 Test Compound ~ _ _ _ _ 181 219 The following examples are given for the purpose of illustrating this invention.
(continued to the next page) :; , .
~: 30 : :
:
~ 35 ~ .
Preparation of the starting compounds ~or Processes l and 2 S ~ _.
.
1) To a solution of 3-nitrobenzaldehyde ~7 56 g~
and methyl 4,4-dimethoxyacetoacjetate ~7.93 g~ in dried benzene t30 ml~ were added acetic acid (0.18 g) and piperidine (0.17 g), and the mixture was heated under reflux for 3,5 hours, while azeotropically removing the water formed therefrom.
After adding benzene to the reaction mixture 9 the solution was washed successively with water, diluted aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of sodium chloride, in turn and then dried. Removal o~ the solvent under reduced pressure gave an oily residue ~15.74 g), which was chromatographed ove~ silica gel (470 g) with a mixture of benzene and ethyl acetate ~25:1 by volume as an eluent to give a yellow oil (8.06 g) of methyl 4,4-dime~hoxy-2-~3-nitTobenzylidene)-acetoaceta~e (a mixture of cis and trans isomers).
25N.M.R. ~ppm (CDC~3) : 3.45 (s)} ~6H) 3.48 (s) ~ 3-8~ ~5)} ~3H) 4- (S) }(lH), :~ 3.91 (s) 5.08 (s) 7.2S - 8.4 ~5H, m).
The ~ollowing compounds were obtained in sub-stan~ially the same manner as that of prepaTation 1 .
~; 35 :
, , ' ~ ' ' 2) Methyl 4,4-dimethoxy-2-(2-me~hylbenzylidene)-- acetoacetate ~a mixture of cis and trans isomers), N.M.R. ~ppm (CDC~3) : 2.33 (3M, s), 3.Z3 tS) 3,42 ~s) 3.64 (s)}~3H) 4-53 (s)}~lH), 3.79 (s) 5.04 (5) 6.8-7.4 ~4H, m), 7-97 ts)}(lH) ' 8.09 ts) 3) Methyl 2-(2-chlorobenæyiidine)-4,4-dimethoxy-acetoacetate ~a mixture of cis and trans isomers).
N.M.R. ~ppm (CDC~3) : 3.28 ~s) 3.41 (s) 3,71 ts)}t3H) 4.68 tS) ~lH), 3.81 (s) 5.~ ~s) 7 7,5 ~4H, m), 8-02 (s) }~lH).
8.12 (s) 4) Methyl 4,4-dimethoxy-2-~4-pyridylmethylene)-acetoacetate ~a mix~ure of cis and trans isomers~.
20N.M.R. ~ppm (CDCQ3) : 3~41 ~s)}(6H) 3.48 ~s) 3.82 ts)}(3H)~ 4-82 (s)}~lHj, 3.89 (s~ 5.06 ~s) ; 7.1-7.4 t2H~ m), 7.73 (s3 7.83 (s) 8.5-8.8 (2H, m).
5) Methyl 2-(2-trifluoromethylbenzylidene)-4,4-dimethoxyacetoace~ate (a mixture of cis and ~ans isome~s), N.M.R. ~ppm ~CDCQ3) : 3.Z8 (s) 3.42 (s) 3.61 ts))~3H)~ 4-62 ~s)}tlH)9 3.84 ts) 5.~6 (s) 7.2-~7.8 t4H, m) 7 8.0-8,14 tlH, m).
6) ~ Methyl 4,4-dimethoxy-2-~2-methoxybenzylidene)-- : :
~7 1~7 -.
acetoacetate (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 3-39 (s)}(6H) 3.47 (s) 3.78 (s)}(6H) 4-77 (9)}~lH), 3.88 (s) 5.16 (s) 6.7-7.2 tm~ } (4H) 8-15 (s) } (lH) 7.3-7.9 (~) 8.23 ts) 7) Methyl 2-(2-allyloxyb~nzylidine)-4,4-dimethoxy-~
acetoacetate (a mixture of cis;and trans isomers).
N.M.R. ~ppm ~CDCQ3) : 3-3 (s)}(6H), 3,4 (s) 3.73 ~5) } ~3H), 4.54 t2H~ m), 3,78 (s) 4,71 (53 } (lH), 5.1-5,5 ~2H, m), 5.07 (s) 5.8-6.22 ~lH, m), 6.7-7.0 ~m) } (4H
7.2-7.4 ~m) 8.14 (5) }(lH).
8.23 ts) 8) Methyl 4,4-dimethoxy-2-(2-thenylidene)acetoacetate ~a mixture of cis and trans isomers).
N.M.R. ~ppm ~CD~Q3) : 3.45 (6H, s), 3.88 ~s) ~: ~: 3.9S ~s) S.ll ~s)}~lH~ 7-7.8 ~3H, m), 5.17 ~s) 7.93 ~s) 8.06 (s)
20N.M.R. ~ppm (CDCQ3) : 3~41 ~s)}(6H) 3.48 ~s) 3.82 ts)}(3H)~ 4-82 (s)}~lHj, 3.89 (s~ 5.06 ~s) ; 7.1-7.4 t2H~ m), 7.73 (s3 7.83 (s) 8.5-8.8 (2H, m).
5) Methyl 2-(2-trifluoromethylbenzylidene)-4,4-dimethoxyacetoace~ate (a mixture of cis and ~ans isome~s), N.M.R. ~ppm ~CDCQ3) : 3.Z8 (s) 3.42 (s) 3.61 ts))~3H)~ 4-62 ~s)}tlH)9 3.84 ts) 5.~6 (s) 7.2-~7.8 t4H, m) 7 8.0-8,14 tlH, m).
6) ~ Methyl 4,4-dimethoxy-2-~2-methoxybenzylidene)-- : :
~7 1~7 -.
acetoacetate (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 3-39 (s)}(6H) 3.47 (s) 3.78 (s)}(6H) 4-77 (9)}~lH), 3.88 (s) 5.16 (s) 6.7-7.2 tm~ } (4H) 8-15 (s) } (lH) 7.3-7.9 (~) 8.23 ts) 7) Methyl 2-(2-allyloxyb~nzylidine)-4,4-dimethoxy-~
acetoacetate (a mixture of cis;and trans isomers).
N.M.R. ~ppm ~CDCQ3) : 3-3 (s)}(6H), 3,4 (s) 3.73 ~5) } ~3H), 4.54 t2H~ m), 3,78 (s) 4,71 (53 } (lH), 5.1-5,5 ~2H, m), 5.07 (s) 5.8-6.22 ~lH, m), 6.7-7.0 ~m) } (4H
7.2-7.4 ~m) 8.14 (5) }(lH).
8.23 ts) 8) Methyl 4,4-dimethoxy-2-(2-thenylidene)acetoacetate ~a mixture of cis and trans isomers).
N.M.R. ~ppm ~CD~Q3) : 3.45 (6H, s), 3.88 ~s) ~: ~: 3.9S ~s) S.ll ~s)}~lH~ 7-7.8 ~3H, m), 5.17 ~s) 7.93 ~s) 8.06 (s)
9~: Methyl 2-~2,4-dichlorobenzylidine)-4,4-dimethoxy-acetoacetate ~a mixture of cis and trans isomers?.
: 30 ~N.M.R. : ~ppm ~CDC~3) : 3.39 ~s)}~6~) :
:: 3.47 ~s) 3.77 tS)}(3~) 4-77 ~s)}~lH),~
3.88 (s) 5.01 ~s) .2-~:.5 ~3H, m), 7.97 (s)} ~j~H).
8.08 (s) E - 3:
~ ~: ' ' :
lO) ~lethyl 2-(3,4-dichlorobenzylidene)-4,4-dimethoxyacetoacetate (one of cis and trans isomers), mp 86.5 - 87.5C.
11) Methyl 4,4-dimethoxy-2-(3,4-dimethoxybenzylidene)-acetoacetate (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 3.43 (s) }~6H
3 49 (s) 3-923 (5)~ (9H), i S 10 (s) 3.97 (s) 6 6 - 7.4 (3H, m) J 7.80 ~5) ~tlH)~
7 89 (s) , (12) 2-Phenoxyethylester of 2-(2-trifluoromethyl-benzylidene)acetoacetic acid (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 2-18 (5) }(3H), 2.47 (s) 3. 9-4 . 9 (4H, m), 6.8-8.2 (lOH, m).
(13) 2-ChloroethyI ester of Z-(2-trifluoro-methylbenzylidene)acetoacetic acid (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 2.18 (5) } (3H~
2.46 (s) ~` 25 3 SO ~t, J-6Hz) } (2H), 3.76 (t~ J~6Hz) 4.34 (t, J=6Hz) } ~2H) 7 3-7 9 (4~, m), ` 4.51 tt, J=6Hz) 7 95 (q, J'2-2HZ) } tlH).
8.04 (q, J=2.2Hz) - .
(14) 2-Ethoxyethyl ester of 2-(2-trifluoromethyl-benzylidene~acetoacetic acid (a mixture of cis and trans isomers).
~ i .
.
7 ~' N-M-R- ~ppm (CCQ4) : l.10 (t, J=7Hz) }~3~) 1.18 (t, J~7Hz) 2.11 (5) }(3H) 3.1-3.8 t4H, m), 2.38 (s) 4,1-4.5 ~2H, m), 7.3-8.0 (5H~ m~.
~15) 2-Benzyloxyethyl ester of 2-(2 trifluoro-methylbe~zylidene)acetoacetic acid (a mixture of cis and trans isomers).
N.M.R~ ~ppm (CC~4) : 2-10 (5) }~3H), 1~ 2.37 (s) 4.1-4.7 (m~ 7,2-8.0 tlOH, m) 4,37 (s) ~ (4H), 4.53 ~s) J
lS (continued to the next page) ~ ~ ' ,:
~ 25 :
.~
: ~ . : . , ~ ; 30 ! , ~ . ; :
~ E - 5 :
, ~: .
. . , 7~17 `.
Preparation of the object compounds ~or this invention:
Exam~e 1 1) A mixture of methyl 4,4-dimethoxy-2-t3-nitrobenzylidene)acetoacetate (8.0 g) and isopropyl 3-aminocrotona~e ~4.07 g) was Xeated at 70C for an hour with stirring, and the sti~ring was continued at 100C for an h~ur and at 120C for additional 2.5 hours. After dissolving the reaction mix~ure in ethyl acetate, the solution was washed with wate~ and an aqueous solution of sodium chloride, dried over magnesium sulfate and then evaporated to dryness under reduced pressure to give a yellow-orange oil (11.0~ g) of isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-t3-: nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.
~: N.M.R. ~ppm (CDCQ~3) : 1.13 (d, J=7.0HZ) 1.27 (d, J-7.GHz) 2.40 (3H7 s), 3.47 (s) }(6H)~
: . 3.50 ~s) :~ 25 3.69 ~3H, s), 5.0 ~lHJ heptet, J=7.0Hz), 5.17 (lH9 s), 6.04 ~lH, s), : . 6.92 (lH, broad s), 7.2-8.2 (4H, m).
2) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-phenyl-1~4-dihydropyridine-3-carboxylic acid was prepared by reacting methyl 2-benzylidene-4,4-dime~hoxyacetoacetate, whichiwas 1~ ~7 ~ ~'7 Z~
obtained from benzaldehyde and methyl 4,4-dimethoxyacetoacetate according to the same manner as that of Preparation l, with isopropyl 3-amino-crotonate in substantially the same manner as that of Example l-l).
N.M.R ~ppm (CDCQ3) : l.ll t3H, d, J~6.5Hz)7 1.23 (3H, d~ J=6.5Hz), 2 37 (3H, s~, 3.42 t3H, s3, 3.46 (3H, s), 4.96 (lH, hep~et, J=6.5Hz), 5,03 (lH, s), 6,03 (lH, s)~ 6.73 (lH, s), 7.0-7.4 (SH, m).
The following examples are prepared in substan-tially the same manner as that of Example l-l).
3) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-(2-tolyl)-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.07 ~ 3H, d~ J=6.~5Hz), l.21 ~3H, d, J=6.SHz), 2.32 (3H, s), 2.55 ~3H, s), 3.41 (3H~ s), 3.44 (3H, s), 3.62 (3H, s), 4.96 (lH, hep~et, : J~6.5Hz), 5.20 (lH, 5)7 5.97 (lH, s), 6.65 ~lH, s), 6.9-7.4 ~4H, m~.
. 4) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-(4-pyridyl)-l, 4-dihydro-::~ 25 pyridine-3-carboxylic acid, mp 115-117C.
S) Isopropyl ester of 4- t2-chlorophenyl)-5-methoxycarbonyl-6-dimethoxymethyl-Z-methyl-1,4-~ ~ dihydropyridine-3-carboxylic acid, mp 86-87.5C.
:~ 6) Isopropyl esteT of 4-~2-trifluoromethylphenyl)-` 30 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-l,4-dihydropyridin~-3-carboxylic acid, mp 9~-94C.
7) Isopropyl~ester of 5-methoxycarbonyl-6-dimethoXymethyl-4-(2-methoxyphenyl)-2-methyl-l,4-~:: dihydropyridine-3-carboxylic acid, mp llO-l~I.5C.
:~ ~ 35 8) Isopropyl es~er of 4-(2-allyloxyphenyli)-S-~ E - 7 1~ 7 methoxyoarbo~yl-6-dimethoxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDC~3) : l.01 (3H, d, J=6,5Hz3, 1.21 ~3H, d, J~6.5Hz3, 2.33 (3H, s), 3.46 (6H, s), 3.63 (3H, s), 4.4-6.3 (8H, m), 6.60 (lH~ broad s)~
6.7-7.5 (4H, m), 9) Isopropyl ester of 5-methoxycarbonyl-6-dime thoxymethyl-2-methyl-4-(Z-thienyl)-1,4-dihydro-
: 30 ~N.M.R. : ~ppm ~CDC~3) : 3.39 ~s)}~6~) :
:: 3.47 ~s) 3.77 tS)}(3~) 4-77 ~s)}~lH),~
3.88 (s) 5.01 ~s) .2-~:.5 ~3H, m), 7.97 (s)} ~j~H).
8.08 (s) E - 3:
~ ~: ' ' :
lO) ~lethyl 2-(3,4-dichlorobenzylidene)-4,4-dimethoxyacetoacetate (one of cis and trans isomers), mp 86.5 - 87.5C.
11) Methyl 4,4-dimethoxy-2-(3,4-dimethoxybenzylidene)-acetoacetate (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 3.43 (s) }~6H
3 49 (s) 3-923 (5)~ (9H), i S 10 (s) 3.97 (s) 6 6 - 7.4 (3H, m) J 7.80 ~5) ~tlH)~
7 89 (s) , (12) 2-Phenoxyethylester of 2-(2-trifluoromethyl-benzylidene)acetoacetic acid (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 2-18 (5) }(3H), 2.47 (s) 3. 9-4 . 9 (4H, m), 6.8-8.2 (lOH, m).
(13) 2-ChloroethyI ester of Z-(2-trifluoro-methylbenzylidene)acetoacetic acid (a mixture of cis and trans isomers).
N.M.R. ~ppm (CDCQ3) : 2.18 (5) } (3H~
2.46 (s) ~` 25 3 SO ~t, J-6Hz) } (2H), 3.76 (t~ J~6Hz) 4.34 (t, J=6Hz) } ~2H) 7 3-7 9 (4~, m), ` 4.51 tt, J=6Hz) 7 95 (q, J'2-2HZ) } tlH).
8.04 (q, J=2.2Hz) - .
(14) 2-Ethoxyethyl ester of 2-(2-trifluoromethyl-benzylidene~acetoacetic acid (a mixture of cis and trans isomers).
~ i .
.
7 ~' N-M-R- ~ppm (CCQ4) : l.10 (t, J=7Hz) }~3~) 1.18 (t, J~7Hz) 2.11 (5) }(3H) 3.1-3.8 t4H, m), 2.38 (s) 4,1-4.5 ~2H, m), 7.3-8.0 (5H~ m~.
~15) 2-Benzyloxyethyl ester of 2-(2 trifluoro-methylbe~zylidene)acetoacetic acid (a mixture of cis and trans isomers).
N.M.R~ ~ppm (CC~4) : 2-10 (5) }~3H), 1~ 2.37 (s) 4.1-4.7 (m~ 7,2-8.0 tlOH, m) 4,37 (s) ~ (4H), 4.53 ~s) J
lS (continued to the next page) ~ ~ ' ,:
~ 25 :
.~
: ~ . : . , ~ ; 30 ! , ~ . ; :
~ E - 5 :
, ~: .
. . , 7~17 `.
Preparation of the object compounds ~or this invention:
Exam~e 1 1) A mixture of methyl 4,4-dimethoxy-2-t3-nitrobenzylidene)acetoacetate (8.0 g) and isopropyl 3-aminocrotona~e ~4.07 g) was Xeated at 70C for an hour with stirring, and the sti~ring was continued at 100C for an h~ur and at 120C for additional 2.5 hours. After dissolving the reaction mix~ure in ethyl acetate, the solution was washed with wate~ and an aqueous solution of sodium chloride, dried over magnesium sulfate and then evaporated to dryness under reduced pressure to give a yellow-orange oil (11.0~ g) of isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-t3-: nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.
~: N.M.R. ~ppm (CDCQ~3) : 1.13 (d, J=7.0HZ) 1.27 (d, J-7.GHz) 2.40 (3H7 s), 3.47 (s) }(6H)~
: . 3.50 ~s) :~ 25 3.69 ~3H, s), 5.0 ~lHJ heptet, J=7.0Hz), 5.17 (lH9 s), 6.04 ~lH, s), : . 6.92 (lH, broad s), 7.2-8.2 (4H, m).
2) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-phenyl-1~4-dihydropyridine-3-carboxylic acid was prepared by reacting methyl 2-benzylidene-4,4-dime~hoxyacetoacetate, whichiwas 1~ ~7 ~ ~'7 Z~
obtained from benzaldehyde and methyl 4,4-dimethoxyacetoacetate according to the same manner as that of Preparation l, with isopropyl 3-amino-crotonate in substantially the same manner as that of Example l-l).
N.M.R ~ppm (CDCQ3) : l.ll t3H, d, J~6.5Hz)7 1.23 (3H, d~ J=6.5Hz), 2 37 (3H, s~, 3.42 t3H, s3, 3.46 (3H, s), 4.96 (lH, hep~et, J=6.5Hz), 5,03 (lH, s), 6,03 (lH, s)~ 6.73 (lH, s), 7.0-7.4 (SH, m).
The following examples are prepared in substan-tially the same manner as that of Example l-l).
3) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-(2-tolyl)-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.07 ~ 3H, d~ J=6.~5Hz), l.21 ~3H, d, J=6.SHz), 2.32 (3H, s), 2.55 ~3H, s), 3.41 (3H~ s), 3.44 (3H, s), 3.62 (3H, s), 4.96 (lH, hep~et, : J~6.5Hz), 5.20 (lH, 5)7 5.97 (lH, s), 6.65 ~lH, s), 6.9-7.4 ~4H, m~.
. 4) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-(4-pyridyl)-l, 4-dihydro-::~ 25 pyridine-3-carboxylic acid, mp 115-117C.
S) Isopropyl ester of 4- t2-chlorophenyl)-5-methoxycarbonyl-6-dimethoxymethyl-Z-methyl-1,4-~ ~ dihydropyridine-3-carboxylic acid, mp 86-87.5C.
:~ 6) Isopropyl esteT of 4-~2-trifluoromethylphenyl)-` 30 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-l,4-dihydropyridin~-3-carboxylic acid, mp 9~-94C.
7) Isopropyl~ester of 5-methoxycarbonyl-6-dimethoXymethyl-4-(2-methoxyphenyl)-2-methyl-l,4-~:: dihydropyridine-3-carboxylic acid, mp llO-l~I.5C.
:~ ~ 35 8) Isopropyl es~er of 4-(2-allyloxyphenyli)-S-~ E - 7 1~ 7 methoxyoarbo~yl-6-dimethoxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDC~3) : l.01 (3H, d, J=6,5Hz3, 1.21 ~3H, d, J~6.5Hz3, 2.33 (3H, s), 3.46 (6H, s), 3.63 (3H, s), 4.4-6.3 (8H, m), 6.60 (lH~ broad s)~
6.7-7.5 (4H, m), 9) Isopropyl ester of 5-methoxycarbonyl-6-dime thoxymethyl-2-methyl-4-(Z-thienyl)-1,4-dihydro-
10 pyridi~e-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.22 (3H, d, J=6.5Hz), 1.28 (3H, d, J=6.5Hz), 2.37 (3H, s), 3,43 (3H, s), 3.49 (3H, s), 3.76 (3H, s), 5.07 (lH, heptet, J=6.5Hz), 5.38 ~lH, s3, lS . 6,04 (lH, s), 6,65-7.45 (4H, m).
10) Isopropyl ester of 4- (2,4-dichlorop~enyl) -5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-1,4-: dihydropyridine-3-carbo~xylic acid.
: N.M.R. ~ppm ~CDC~3) : 1.07 ~3H, d, J=6.5Hz), 1.21 (3H, d, J-6.5Hz), ~.34 ~3H, s), :~ 3.42 (3H, s), 3.46 ~3H, s), 3.64 (3H, s)~
4.97 (lH, heptet, J-6.5Hz), 5.39 (lH9 s~, S,g6 ~lH, s), 6.65 ~lH, s), 7.0-7.4 (3H, ~).
N.M.R. ~ppm ~CDCQ3) : 1.22 (3H, d, J=6.5Hz), 1.28 (3H, d, J=6.5Hz), 2.37 (3H, s), 3,43 (3H, s), 3.49 (3H, s), 3.76 (3H, s), 5.07 (lH, heptet, J=6.5Hz), 5.38 ~lH, s3, lS . 6,04 (lH, s), 6,65-7.45 (4H, m).
10) Isopropyl ester of 4- (2,4-dichlorop~enyl) -5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-1,4-: dihydropyridine-3-carbo~xylic acid.
: N.M.R. ~ppm ~CDC~3) : 1.07 ~3H, d, J=6.5Hz), 1.21 (3H, d, J-6.5Hz), ~.34 ~3H, s), :~ 3.42 (3H, s), 3.46 ~3H, s), 3.64 (3H, s)~
4.97 (lH, heptet, J-6.5Hz), 5.39 (lH9 s~, S,g6 ~lH, s), 6.65 ~lH, s), 7.0-7.4 (3H, ~).
11) Isopropyl este~ o~ 4- t3,4-dichlorophenyl) -5-: methoxycarbonyl-6-dimethoxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.18 ~d, J=6.5Hz) } t6H) 5 (d, J=6~5Hz) : 30 2.39 (3H~ s), 3.46 (3H, s), 3~50 (3H, s),:
3.70 ~3H, s:), 5.00 ~lH, s3, S.00 (lH, hept~t, J=6.5Hz), 6.03 ~l~, s), 6.75 (lH, s), 7.0-7.5 ~3H, m).
N.M.R. ~ppm (CDCQ3) : 1.18 ~d, J=6.5Hz) } t6H) 5 (d, J=6~5Hz) : 30 2.39 (3H~ s), 3.46 (3H, s), 3~50 (3H, s),:
3.70 ~3H, s:), 5.00 ~lH, s3, S.00 (lH, hept~t, J=6.5Hz), 6.03 ~l~, s), 6.75 (lH, s), 7.0-7.5 ~3H, m).
12) Isopropyl ester of 5-methoxycarbonyl-6-i dimethoxymethyl 4-(3,4-dimethoxyphenyl)-2-me!thyl-1,4-~ .
' E - 8 1~7~17 f. ?
dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.16 (3H, d, J-6.5Hz), 1.25 t3H, d, J=6.SHz), 2,37 (3H, s), 3 41 (s)~
3;43 (S)J(6H), 3.4~ (5) 3.79 (3H, s), 3.84 (6H, s), 4.99 (lH, s), 4.99 (lH9 heptet, J~6.5Hz), 6.03 ~lH, s), 6.6-7.3 (4H, m~.
' E - 8 1~7~17 f. ?
dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.16 (3H, d, J-6.5Hz), 1.25 t3H, d, J=6.SHz), 2,37 (3H, s), 3 41 (s)~
3;43 (S)J(6H), 3.4~ (5) 3.79 (3H, s), 3.84 (6H, s), 4.99 (lH, s), 4.99 (lH9 heptet, J~6.5Hz), 6.03 ~lH, s), 6.6-7.3 (4H, m~.
13) Dipropyl ester o 2-met~yl-4-(3-nitrophenyl)-6 dipropoxym~thyl-1,4-dihydropyridine-3,5-dicarboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 2.37 (3H, s), 5.02 (lH, s~, 6.21 ~lH, s), 6.88 (lH, broad s).
N.M.R. ~ppm ~CDCQ3) : 2.37 (3H, s), 5.02 (lH, s~, 6.21 ~lH, s), 6.88 (lH, broad s).
14) 2-~N-Benzyl-N-methylamino)ethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-~2-trifluoromethyl-phenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, N.M.R, ~ppm (CDCS3) ~ 1.3 (9H, m), 2017 :~ (3H~ s), 2.33 t3H, s), 2.60 ~2H, t, J-6Hz), 3.48 (2H, s), 3.4-4.4 (8H, m), :~ 5.63 (lH, s), 6.13 ~lH, s), 6.71 (lH, s), 7.1-7.6 (9H, m).
. lS) 2-Phenoxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2~trifluoromethylphenyl~-2-methyl-1,4-dihydropyridine-3-carboxylic ~cid.
N.M.R. ~ppm (CDCQ3) : 1.0 ~o 1.5 (9H, m), 2.37 (3H, s), 3.5-4.~ (lOH, m), 5.67 ~ (lH, s~, 7.12 (lH, s), 6.7-7.8 tlOH, m) A
:~ 16) 2-Chloroethyl ester o~ 5-ethoxycarbonyl-6' : 30 diethoxymethyl-4-~2-tri~luoromethylp~enyl)-2-methyl-: 1,4-dihydropyridine-3-carboxylic acid.
:~ N.M.R. ~ppm ~CCQ~) : 1.0-1.5 (6H, m~,`2.39 3H, s)~ 3.4-4.5 ~lOH, m)~ 5~5-5.7 ~ (lH, m), 6,10 (lH, s), 6.55 (lH,-s), ;~ 35 7-7.6 (4H, m). i/
~ ~ E - g ' :: .
~17~17 17) 2-~thoxyethyl ester o 5-ethoxycarbonyl-6-diethoxymethyl-4-~2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxy.lic acid.
N.M.R. ~ppm ~CCQ~ L.0-1.4 (12H~ m), S ~.38 (3H, s), 3.3-4.3 ~12H, m), 5-5-5.7 tlH, m), 6.10 (lH, s), 6.47 (lH, s~, 7.2-7.7 (4H, m~.
18) 2-Benzyloxyethyl ester of 5-ethoxycarbonyl-6-diethoxyme~hyl-4-(2-trifluorométhylphenyl~-2-me~hyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.0-1.6 t9H, m), 2.32 t3H~ s), 3.4-4.4 (lOH, m), 4.47 ~2H, s), 5.6-S, 7 (lH, m), 6.11 (lH, s), 6.6-6.8 ~lH, broad s), lS 7.2-7.7 ~9H, m).
(continued to the next page) .
~. ~, :~
~ .
~ ~ 30 -~ 35 .
E ~ 10 .
7~17 Example 2 1) A mixture of 2-phenoxyethyl ester of 2-(2-trifluoromethylbenzylidene)acetoacetate (19.62 g~ and ethyl 2-amino-4,4-diethoxycrotonate (ll.9S g) was heated for 20 hours at 100 to 110C and for additional 12 hours à~ 120 to 130~C. The resultant mixture was dissolved in ethyl acetate and washed with water and then dried over anhydrous magnesium sulfate. The sol~ent was removed by distil:la~ti~n to give a crude oil (27.7 g), which was chromatographed o~er silica gel with a mixture of benzene and ethyl acetate ~50:1 by volume) as an eluent to gi~e 2-phenoxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-trifluoro-methylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid (19.34 g~.
N.M.R. ~ppm (CDCQ3) : 1.0 to 1.5 (9H, m), 2.37 (3H, s), 3.5-4.6 (lOH, m), 5.67 (lH, s) 9 7.12 (lH, s), 6,7-7.8 (lOH, m).
The following compounds were obtained in substan-tially the same manner as that of Example 2-1).
2~ 2-Chloroethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-trifluoromethylphenyl)-2-~ethyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CCQ4) : 1.0-1.5 (6H, m), 2.39 t3H,.
s3, 3.4-4.5 (lOH, m), 5.5-5.7 (lH, m), : 6.10 (lH, s), 6.55 (lH, s), 7-7.6 ~4H, m)- .
~ 3) 2-E*hoxyethyl ester o 5-ethoxycarbonyl-6-:~ 30 diethoxymethyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid. :
N.M.R. ~ppm (CCQ4) : 1.0-1.4 (12H, m), 2.38 (3H, s), 3.3-4.3 (12H, m), -. 505-5.7 (lH, m), 6.10 (lH, s), 35. 6.47 (lH, s), 7.2-7.7 (4H, ~.
~ E - 11 4) 2-Benzyloxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-tri~luoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.0-1.6 (9H, m~, 5 ~- 2.32 (3H, s), 3.4-4.4 (lOH, m), 4.47 (2H, s), 5.6-5.7 (lH, m) 7 6.11 (lH, s), 6.6-6.8 (lH, broad s~, 7.2-7.7 ~9H, m), S) 2-(N-Benzyl-N-methylamino)ethyl ester of 5-ethoxycarbonyl-6-dicthoxymethyl-4-~2-trifluoromethyl-phenyl)-2-methyl-1,4-dihydropyridine-3 carboxylic acid.
N.M.R. ~ppm (CDCQ3) ~ 1.3 (9H, m), 2,17 t3H, s), 2.33 (3HJ s), 2.60 (2H, t, J=6Hz), 3.48 (2H, s), 3,4-4.4 (8H, m), 5.63 (lH, s~, 6.13 (lH, s), 6.71 (lH, s), 7.1-7.6 (9H, m).
6) Isopropyl ester o 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-: 3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.13 (d, J=7.0Hz) }(6H
1.27 ~d, J=7.OHz) 2.40 ~3H, 5), 3 47 ~5) }(6H), ~ 3.50 (s) :~ 3,69 (3H, s), 5.0 (lH, hep~et, J-7.0Hz), ;:~ 25 5.17 (lH, s), 6~04 (lH, s), 6.92 (lH, broad s)~ 7.2-8.2 ~4H, m).
:~ 7) Isop~opyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-~-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid.
~ 30 N.M.R. ~ppm (CDCQ3) : 1.11 (3H, d, J=6.5Hz), : 1.23 (3H, d, J=6.5Hz)~ 2.37 ~3H, s), ::: 3.42 (3H, s)~ 3.46 (3H, s), 4.96 (lH, ~- heptet, Ja6.5Hz~, 5.03 (lH, s3, 6.03 (lH, s), 6.73 (lH, s), ,7.0-7.4 (5H, m).
~ ~ E - 12 : ~ .
7~7 -`:
3~
8) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-(2-tolyl)-1, 4 - dihydro -pyridine-3-carboxylic acid.
N~M.R. ~ppm ~CDCQ3) : 1.07 (3H, d9 J-6.5Hz), S 1.21 ~3H, d, J=6.SHz~, 2,32 (3H, s), .SS (3H, s), 3.41 t3H, s~, 3.44 (3H, s), 3.62 (3H, s), 4,96 ~lH, heptet, J-6..5Hz), 5.20 (lH~ s~, 5.97 (lH, s), 6.65 (lH, s), 6.9-7.4 (4H,.m).
9) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid.
I.R. v NUa~ol : 3300, 3200, 3070, 1710 (shoulder), lS 1700~ 1650, 1603, 1518, 1278, 1269, 1190, 1090, 960, 782 cm 1 10) Isopropyl ester of 4-(2-chlorophenyl)-5-methoxy-: carbonyl-6-dime thoxyme thyl - 2 -me thyl -1, 4 - dihydropyridine-3-carboxylic acid~ mp 86-87.5C.
Isopropyl ester of 4-(2-trifluoromethylphenyl)-: 5 -me thoxy carbonyl-6-dime~hoxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
: : 25 I.R. ~ ma~ : 3400- 1720, 1690, 1653, 1493, : 1319, 1310? 1278, 12067 lO9S, 1035, 951, 768 cm :~ 12) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy ~: methyl-4-(2-methoxyphenyl)-2-methyl-1,4-dihydropyridine-3-c~rboxylic:acid, mp 110-111.5C.
13) Isopropyl ester of 4-(2-allyloxyphenyl)-5-: methoxycarbonyl-6-dimethoxyme~hyl-2-methyl-1,4 dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.01 (3H~ d, ~;=6.SHz)~
: 35 1.21 (3H, d, J=6.5Hz), 2.33 (3H, s), -'"`' ` ;:
' 7~7 i -`
3.46 (6H, s), 3.63 ~3H, s~, 4.4-6.3 (8H, m), 6.60 (lH, broad s), 6.7-7.5 (4H, m) 14) Isopropyl ester of S-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-(~ hienyl~1,4-dihydro- --pyridine-3-carboxylic acid.
N.M.R. ~ppm (CDC~3) : 1.22 (3H, d, J=6.5Hz), 1.28 (3H, d, J36.5Hz) 7 2.37 (3H, s), 3.43 (3H, s)~ 3.49 (3H, s)~ 3.76 (3H, s~, 5.07 (lH~ heptet, J~6.5Hz~, 5.3B (lH, s ), 6.04 (lH, s), 6.65-7 45 (4H7 m).
. lS) 2-Phenoxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2~trifluoromethylphenyl~-2-methyl-1,4-dihydropyridine-3-carboxylic ~cid.
N.M.R. ~ppm (CDCQ3) : 1.0 ~o 1.5 (9H, m), 2.37 (3H, s), 3.5-4.~ (lOH, m), 5.67 ~ (lH, s~, 7.12 (lH, s), 6.7-7.8 tlOH, m) A
:~ 16) 2-Chloroethyl ester o~ 5-ethoxycarbonyl-6' : 30 diethoxymethyl-4-~2-tri~luoromethylp~enyl)-2-methyl-: 1,4-dihydropyridine-3-carboxylic acid.
:~ N.M.R. ~ppm ~CCQ~) : 1.0-1.5 (6H, m~,`2.39 3H, s)~ 3.4-4.5 ~lOH, m)~ 5~5-5.7 ~ (lH, m), 6,10 (lH, s), 6.55 (lH,-s), ;~ 35 7-7.6 (4H, m). i/
~ ~ E - g ' :: .
~17~17 17) 2-~thoxyethyl ester o 5-ethoxycarbonyl-6-diethoxymethyl-4-~2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxy.lic acid.
N.M.R. ~ppm ~CCQ~ L.0-1.4 (12H~ m), S ~.38 (3H, s), 3.3-4.3 ~12H, m), 5-5-5.7 tlH, m), 6.10 (lH, s), 6.47 (lH, s~, 7.2-7.7 (4H, m~.
18) 2-Benzyloxyethyl ester of 5-ethoxycarbonyl-6-diethoxyme~hyl-4-(2-trifluorométhylphenyl~-2-me~hyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.0-1.6 t9H, m), 2.32 t3H~ s), 3.4-4.4 (lOH, m), 4.47 ~2H, s), 5.6-S, 7 (lH, m), 6.11 (lH, s), 6.6-6.8 ~lH, broad s), lS 7.2-7.7 ~9H, m).
(continued to the next page) .
~. ~, :~
~ .
~ ~ 30 -~ 35 .
E ~ 10 .
7~17 Example 2 1) A mixture of 2-phenoxyethyl ester of 2-(2-trifluoromethylbenzylidene)acetoacetate (19.62 g~ and ethyl 2-amino-4,4-diethoxycrotonate (ll.9S g) was heated for 20 hours at 100 to 110C and for additional 12 hours à~ 120 to 130~C. The resultant mixture was dissolved in ethyl acetate and washed with water and then dried over anhydrous magnesium sulfate. The sol~ent was removed by distil:la~ti~n to give a crude oil (27.7 g), which was chromatographed o~er silica gel with a mixture of benzene and ethyl acetate ~50:1 by volume) as an eluent to gi~e 2-phenoxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-trifluoro-methylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid (19.34 g~.
N.M.R. ~ppm (CDCQ3) : 1.0 to 1.5 (9H, m), 2.37 (3H, s), 3.5-4.6 (lOH, m), 5.67 (lH, s) 9 7.12 (lH, s), 6,7-7.8 (lOH, m).
The following compounds were obtained in substan-tially the same manner as that of Example 2-1).
2~ 2-Chloroethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-trifluoromethylphenyl)-2-~ethyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CCQ4) : 1.0-1.5 (6H, m), 2.39 t3H,.
s3, 3.4-4.5 (lOH, m), 5.5-5.7 (lH, m), : 6.10 (lH, s), 6.55 (lH, s), 7-7.6 ~4H, m)- .
~ 3) 2-E*hoxyethyl ester o 5-ethoxycarbonyl-6-:~ 30 diethoxymethyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid. :
N.M.R. ~ppm (CCQ4) : 1.0-1.4 (12H, m), 2.38 (3H, s), 3.3-4.3 (12H, m), -. 505-5.7 (lH, m), 6.10 (lH, s), 35. 6.47 (lH, s), 7.2-7.7 (4H, ~.
~ E - 11 4) 2-Benzyloxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-tri~luoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.0-1.6 (9H, m~, 5 ~- 2.32 (3H, s), 3.4-4.4 (lOH, m), 4.47 (2H, s), 5.6-5.7 (lH, m) 7 6.11 (lH, s), 6.6-6.8 (lH, broad s~, 7.2-7.7 ~9H, m), S) 2-(N-Benzyl-N-methylamino)ethyl ester of 5-ethoxycarbonyl-6-dicthoxymethyl-4-~2-trifluoromethyl-phenyl)-2-methyl-1,4-dihydropyridine-3 carboxylic acid.
N.M.R. ~ppm (CDCQ3) ~ 1.3 (9H, m), 2,17 t3H, s), 2.33 (3HJ s), 2.60 (2H, t, J=6Hz), 3.48 (2H, s), 3,4-4.4 (8H, m), 5.63 (lH, s~, 6.13 (lH, s), 6.71 (lH, s), 7.1-7.6 (9H, m).
6) Isopropyl ester o 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-: 3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.13 (d, J=7.0Hz) }(6H
1.27 ~d, J=7.OHz) 2.40 ~3H, 5), 3 47 ~5) }(6H), ~ 3.50 (s) :~ 3,69 (3H, s), 5.0 (lH, hep~et, J-7.0Hz), ;:~ 25 5.17 (lH, s), 6~04 (lH, s), 6.92 (lH, broad s)~ 7.2-8.2 ~4H, m).
:~ 7) Isop~opyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-~-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid.
~ 30 N.M.R. ~ppm (CDCQ3) : 1.11 (3H, d, J=6.5Hz), : 1.23 (3H, d, J=6.5Hz)~ 2.37 ~3H, s), ::: 3.42 (3H, s)~ 3.46 (3H, s), 4.96 (lH, ~- heptet, Ja6.5Hz~, 5.03 (lH, s3, 6.03 (lH, s), 6.73 (lH, s), ,7.0-7.4 (5H, m).
~ ~ E - 12 : ~ .
7~7 -`:
3~
8) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-(2-tolyl)-1, 4 - dihydro -pyridine-3-carboxylic acid.
N~M.R. ~ppm ~CDCQ3) : 1.07 (3H, d9 J-6.5Hz), S 1.21 ~3H, d, J=6.SHz~, 2,32 (3H, s), .SS (3H, s), 3.41 t3H, s~, 3.44 (3H, s), 3.62 (3H, s), 4,96 ~lH, heptet, J-6..5Hz), 5.20 (lH~ s~, 5.97 (lH, s), 6.65 (lH, s), 6.9-7.4 (4H,.m).
9) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy-methyl-2-methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid.
I.R. v NUa~ol : 3300, 3200, 3070, 1710 (shoulder), lS 1700~ 1650, 1603, 1518, 1278, 1269, 1190, 1090, 960, 782 cm 1 10) Isopropyl ester of 4-(2-chlorophenyl)-5-methoxy-: carbonyl-6-dime thoxyme thyl - 2 -me thyl -1, 4 - dihydropyridine-3-carboxylic acid~ mp 86-87.5C.
Isopropyl ester of 4-(2-trifluoromethylphenyl)-: 5 -me thoxy carbonyl-6-dime~hoxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
: : 25 I.R. ~ ma~ : 3400- 1720, 1690, 1653, 1493, : 1319, 1310? 1278, 12067 lO9S, 1035, 951, 768 cm :~ 12) Isopropyl ester of 5-methoxycarbonyl-6-dimethoxy ~: methyl-4-(2-methoxyphenyl)-2-methyl-1,4-dihydropyridine-3-c~rboxylic:acid, mp 110-111.5C.
13) Isopropyl ester of 4-(2-allyloxyphenyl)-5-: methoxycarbonyl-6-dimethoxyme~hyl-2-methyl-1,4 dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.01 (3H~ d, ~;=6.SHz)~
: 35 1.21 (3H, d, J=6.5Hz), 2.33 (3H, s), -'"`' ` ;:
' 7~7 i -`
3.46 (6H, s), 3.63 ~3H, s~, 4.4-6.3 (8H, m), 6.60 (lH, broad s), 6.7-7.5 (4H, m) 14) Isopropyl ester of S-methoxycarbonyl-6-dimethoxymethyl-2-methyl-4-(~ hienyl~1,4-dihydro- --pyridine-3-carboxylic acid.
N.M.R. ~ppm (CDC~3) : 1.22 (3H, d, J=6.5Hz), 1.28 (3H, d, J36.5Hz) 7 2.37 (3H, s), 3.43 (3H, s)~ 3.49 (3H, s)~ 3.76 (3H, s~, 5.07 (lH~ heptet, J~6.5Hz~, 5.3B (lH, s ), 6.04 (lH, s), 6.65-7 45 (4H7 m).
15) Isopropyl es~er of 4-(2,4-dichlorophenyl~-5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-1,4-15 dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1 07 ~3H, d, J=6,5Hz), 1.21 (3H~ d~ J=6 5HZ) ~ 2.34 (3HJ S~
3.42 (3H, s), 3.46 (3H~. S), 3t64 (3H, s), 4.97 (lH, heptet, J=6.5H7),5.39 (lH, s), 5.96 (lH, sj, 6.65 (lH, s~, 7.0-7.4 (3H, m)
N.M.R. ~ppm (CDCQ3) : 1 07 ~3H, d, J=6,5Hz), 1.21 (3H~ d~ J=6 5HZ) ~ 2.34 (3HJ S~
3.42 (3H, s), 3.46 (3H~. S), 3t64 (3H, s), 4.97 (lH, heptet, J=6.5H7),5.39 (lH, s), 5.96 (lH, sj, 6.65 (lH, s~, 7.0-7.4 (3H, m)
16) Isopropyl ester of 4-(3,4-dichlorophenyl)-5-methoxycarbonyl-6-dimethoxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.18 (d, J-6.5Hz) } ~6H
1.25 (d9 J=6.5Hz) 2.39 (3H~ S), 3.46 (3H, S), 3.50 (3H~ S), 3.70 (3H, s), 5.00 (lH, s), 5.00 (lH, heptet, J=6.SHz~, 6.03 (lH, s), 6~75 ~lH, s), 7.0-7.5 (3H, m).
N.M.R. ~ppm (CDCQ3) : 1.18 (d, J-6.5Hz) } ~6H
1.25 (d9 J=6.5Hz) 2.39 (3H~ S), 3.46 (3H, S), 3.50 (3H~ S), 3.70 (3H, s), 5.00 (lH, s), 5.00 (lH, heptet, J=6.SHz~, 6.03 (lH, s), 6~75 ~lH, s), 7.0-7.5 (3H, m).
17~ Isopropyl ester of 5-me~hoxycarbonyl-6-dimethoxymethyl-4-(3,4-dimethoxyphenyl)-2-methyl-1,4 dihydropyrid1ne-3-carboxylic acid.
N.M.R. ~ppm ~CDCQ3) : 1.16 (3H, d, J-6.5Hz), 1.25 (3H~ d, J=6.5Hz), 2.37 ~3H, s), . ~ .
. ' ' ' ' l7 0 3~3 3.41 ~S) 3 43 ~S) (6 3.49 ~S) 3.79 (3H, S)V 3.84 (6H, S~J 4.99 (1H, S)7 4 . 99 (1H~ hePtet, J36 . SHZ) ~ 6 . 03 ~1H, S~
6,6-7.3 (4H~ m).
N.M.R. ~ppm ~CDCQ3) : 1.16 (3H, d, J-6.5Hz), 1.25 (3H~ d, J=6.5Hz), 2.37 ~3H, s), . ~ .
. ' ' ' ' l7 0 3~3 3.41 ~S) 3 43 ~S) (6 3.49 ~S) 3.79 (3H, S)V 3.84 (6H, S~J 4.99 (1H, S)7 4 . 99 (1H~ hePtet, J36 . SHZ) ~ 6 . 03 ~1H, S~
6,6-7.3 (4H~ m).
18) Dip~opyl ester of 2-methyl-4-(3-nitrophenyl) -6-dipropoxymethyl-1,4-dihydropyridine-3,5-dicarboxylic acid.
N.M.R. ~ ppm ~CDC Q3) : 2.37 ~3H~ S~ ~ 5 ~ 02 ~1H, S) 6,21 ~lH, s) J 6.88 (lH, broad s).
(continued to the next page) .
, .
~ ~ ~30 3 s .
: ': , ,:
: ~ , ~7 Example 3 1) To a solution of ~-phenoxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-trifluoromethyl-phenyl)-2-methyl 1,4-dihydropyridine 3-carboxylic acid ~15.85 g) in acetone (159 ml) was added 6N
hydrochloric acid.(15.85 ml) at ambient temperature with stirring and the stirring was continued for 1.5 hours, The reaction mixture wa~ neutralized with a saturated aqueous solution of sodium bicarbonate, and the acetone was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water and then dried. Removal of the solvent gave an oil (13.56 g) of 2-phenoxyethyl ester of 5-ethoxycarbonyl-4-(2-trifluoromethylphenyl)-6-formyl-2-methyl 1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.22 (3H~ t, J~7,5Hz), 2.40 (3H, s~, 4.0-4.6 ~6H, m), 5.71 (lH9 s), 6.7-7.7 (lOH, m), 10.26 (lH, s).
The following compounds were prepared in substan-tially the same manner as that o~ Example 3-1).
2) Isopropyl ester of 6-formyl-5-meth.o.xycarbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxyli~. acidO
3) Isopropyl ester of 6-formyl-5-me~hoxycarbonyl~
2-methyl-4-(2-tolyl)-1,4-dihydropyridine-3-carboxylic : acid, mp 143-144C.
4) Isopropyl ester o 6-formyl-5-methoxycarbonyl-2-methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid, mp 143-145C.
5) Isopropyl ester of 4-~2-chlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 102-103C.
6) Isop~opyl ester of 4-(2-trifluoromethylphenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydro/pyridine-3-carboxylic acid, mp 83-85C.
......... ~ ,.. ... ... ...
7~L~7 3~3 7) Isopr~pyl ester of 6-~ormyl-5-m~thoxycarbonyl-4 - ( 2 -methoxyphenyl ) - 2 -me thyl -1, 4 - dihyclropyridine - 3 -carboxylic acid, mp 142-143C.
8) Isopropyl ester of 4-(2-allyloxyphenyl)-6-formyl-5-methoxyfarbonyl-~-methyl-1,4-dihydropyridine-3-carboxylic acidt mp 103-104 . 5C.
9) Isopropyl ester of 6-formyl- 5-methoxycarbonyl- ~
2-methyl-4-~2-thienyl)-1,4-dihy~ropyridine-3-carboxylic acid, mp 114-116C.
10) Isopropyl ester o 4-(2,4-dichlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.07 ~3H, d, J=6.5Hz), 1.24 ~3H, d, J=6.5Hz), 2,39 (3H, s), lS 3.71 (3H, s), 4.98 ~lH, heptet, J~6.5Hz)9 5.Sl ~lH, s), 6.93 ~lH, s), 7.0-7.4 (3H, m), 10 34 ~lH, s).
ll) Isopropyl ester of 4-(3,4-dichlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 95-96C.
12) Isopropyl ester of 6-formyl-5-methoxycarbonyl-4-~3,4-dimethoxyphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDC~3) : 1.14 ~3H, d~ J=6.5Hz), 1 26 (3H, d, J=6.5Hz), 2.40 ~3H, s), 3.78 ~3H, s), 3.84 ~6H~ s), 4.98 (lH, ` heptet, J-6.5Hz), 5.05 ~lH, s), 6.5-7.3 ~4H, m), 10.44 (lH, s~.
13) Dipropyl ester of 6-formyl-2-methyl-4-~3-nitrophenyl)-1,4-dihydropyridine-395-dicarboxylic acid.
N.M.R. ~ppm (CDCQ3) : 0.87 ~3H~ t, J=7.5Hz), 0.90 (3H, t, J=7.5Hz), 1.55 (2H, sixtet, J~7.5Hz), 1.61 (2H, six~et, J=7.5Hz), 2.44 (3H, s), 4.02 ~2H, t, J=7.5Hz), 4.13 (2H, t, J=7.5Hz~, 5.28 (lH, s), 7.11 ~lH, broad s~, 7.4-8.2 (4H, m), 10.56 ~lH, s).
14) 2-HydToxrethyl ester of 5-ethoxycarbonyl-6-formyl-2-me~hyl-4-~3-nitroph~yl)-1,4-dihydrapyridine-3-carboxylic aîcd.
N.M.R. ~ppm ~CDC~3) : .5.25 (lH, s), 10.50 ~lH, s).
) 2-~thaxyethyl est~r of 5-ethoxycarbonyl-6-~ formyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
. 10 N_~.R. ~ppm tCDCQ3) : 1.14 (t, J-7Hz) } (6H~
1 . Z 6 (t, J~ 7Hz) 2.43 (3H, s), 3.3-3.8 ~4H, m) 9 4,0-4.5 (4H, m~, 5.7-5.8 (lH, m), 6.~-7.0 (lH, m), 7.1-7.8 (4H, m), li 10.27 (lH, s).
16~ 2-Benzyloxye~hyl ester o 5-ethoxycarbonyl-6-~ormyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CCQ4) : 1.23 (3H) t, J-7.5Hz)~
2.40 (3H, s), 3.4-4.5 (6H, m), 4.41 (2H, s), 5.7-5.8 ~lH, m), 6.8-6.9 (lH, m), 7.2-7.8 (9H, m)~
10.28 (lH, s).
17) 2- ~N-Benzyl-N-methylamirlo~ethyl es~er of S-25 . ethoxycarbonyl-6 -formyl- 4- (2 -trifluoromethylphenyl)-~ 2-methyl-1,4-dihydropyridi~e-3-carboxylic acid.
: : N.M.~. ~ppm (CDCQ3) : 1.23 ~3H9 t, J~7Hz), Z.19`(3H, s), 2.41 (3H, s), 2.63 (2H, t, 3=7Hz), 3.51 (2H, s), :~ 30 . 4-4.4 ~4H, m), 5.71 ~lH, broad~s)~
. 6 .91 (lH, broad s), 7.2-7.7 (~H, m~, 10.28 (lH, s~.
(continued to the ne,xt page) `~ 35 1~:L7 Example 4 A mixture of isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl~4-~3-nitrophenyl)-1,4-dihydropyridin-3-carboxylic acid ~11.0 g.) acid (11.0 g.) and 6N hydrochloric acid (11 ml.) in ace-tone ~110 ml.) was stirred at ambient temperature for 4 hours. ~fter removal of the acetone, water ~as added to the reaction mixture and adjusted to pH 7.~
with a saturated aqueous solution of sodium bicarbonate The resultant aqueous solution was e~tracted with ethyl acetate, and the extract was washed with water and dried over anhydrous magnesium sulfate. The removal of the _. solvent gave an oily residue, which was immediately solidified to provide crude yellow-orange crystals of isopropyl ester of 6-formyl-5-methoxycarbonyl-2-methyl-4-~3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.
N~ppm(CDC13) : 1.13(3H, d, J=7H~), 1.28(3H, d, J=7Hz), 1.79(3H, s), 3.80(3H, s), 5.02(1H, heptet, J=7Hz), 5.27(1H, s), 7.11(1H, broad s), 7.4-8.2(4H, m), 10.60 (lE~, 5) `
(continued to the next page) !
N.M.R. ~ ppm ~CDC Q3) : 2.37 ~3H~ S~ ~ 5 ~ 02 ~1H, S) 6,21 ~lH, s) J 6.88 (lH, broad s).
(continued to the next page) .
, .
~ ~ ~30 3 s .
: ': , ,:
: ~ , ~7 Example 3 1) To a solution of ~-phenoxyethyl ester of 5-ethoxycarbonyl-6-diethoxymethyl-4-(2-trifluoromethyl-phenyl)-2-methyl 1,4-dihydropyridine 3-carboxylic acid ~15.85 g) in acetone (159 ml) was added 6N
hydrochloric acid.(15.85 ml) at ambient temperature with stirring and the stirring was continued for 1.5 hours, The reaction mixture wa~ neutralized with a saturated aqueous solution of sodium bicarbonate, and the acetone was removed in vacuo. The residue was dissolved in ethyl acetate, washed with water and then dried. Removal of the solvent gave an oil (13.56 g) of 2-phenoxyethyl ester of 5-ethoxycarbonyl-4-(2-trifluoromethylphenyl)-6-formyl-2-methyl 1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.22 (3H~ t, J~7,5Hz), 2.40 (3H, s~, 4.0-4.6 ~6H, m), 5.71 (lH9 s), 6.7-7.7 (lOH, m), 10.26 (lH, s).
The following compounds were prepared in substan-tially the same manner as that o~ Example 3-1).
2) Isopropyl ester of 6-formyl-5-meth.o.xycarbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxyli~. acidO
3) Isopropyl ester of 6-formyl-5-me~hoxycarbonyl~
2-methyl-4-(2-tolyl)-1,4-dihydropyridine-3-carboxylic : acid, mp 143-144C.
4) Isopropyl ester o 6-formyl-5-methoxycarbonyl-2-methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid, mp 143-145C.
5) Isopropyl ester of 4-~2-chlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 102-103C.
6) Isop~opyl ester of 4-(2-trifluoromethylphenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydro/pyridine-3-carboxylic acid, mp 83-85C.
......... ~ ,.. ... ... ...
7~L~7 3~3 7) Isopr~pyl ester of 6-~ormyl-5-m~thoxycarbonyl-4 - ( 2 -methoxyphenyl ) - 2 -me thyl -1, 4 - dihyclropyridine - 3 -carboxylic acid, mp 142-143C.
8) Isopropyl ester of 4-(2-allyloxyphenyl)-6-formyl-5-methoxyfarbonyl-~-methyl-1,4-dihydropyridine-3-carboxylic acidt mp 103-104 . 5C.
9) Isopropyl ester of 6-formyl- 5-methoxycarbonyl- ~
2-methyl-4-~2-thienyl)-1,4-dihy~ropyridine-3-carboxylic acid, mp 114-116C.
10) Isopropyl ester o 4-(2,4-dichlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDCQ3) : 1.07 ~3H, d, J=6.5Hz), 1.24 ~3H, d, J=6.5Hz), 2,39 (3H, s), lS 3.71 (3H, s), 4.98 ~lH, heptet, J~6.5Hz)9 5.Sl ~lH, s), 6.93 ~lH, s), 7.0-7.4 (3H, m), 10 34 ~lH, s).
ll) Isopropyl ester of 4-(3,4-dichlorophenyl)-6-formyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 95-96C.
12) Isopropyl ester of 6-formyl-5-methoxycarbonyl-4-~3,4-dimethoxyphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm (CDC~3) : 1.14 ~3H, d~ J=6.5Hz), 1 26 (3H, d, J=6.5Hz), 2.40 ~3H, s), 3.78 ~3H, s), 3.84 ~6H~ s), 4.98 (lH, ` heptet, J-6.5Hz), 5.05 ~lH, s), 6.5-7.3 ~4H, m), 10.44 (lH, s~.
13) Dipropyl ester of 6-formyl-2-methyl-4-~3-nitrophenyl)-1,4-dihydropyridine-395-dicarboxylic acid.
N.M.R. ~ppm (CDCQ3) : 0.87 ~3H~ t, J=7.5Hz), 0.90 (3H, t, J=7.5Hz), 1.55 (2H, sixtet, J~7.5Hz), 1.61 (2H, six~et, J=7.5Hz), 2.44 (3H, s), 4.02 ~2H, t, J=7.5Hz), 4.13 (2H, t, J=7.5Hz~, 5.28 (lH, s), 7.11 ~lH, broad s~, 7.4-8.2 (4H, m), 10.56 ~lH, s).
14) 2-HydToxrethyl ester of 5-ethoxycarbonyl-6-formyl-2-me~hyl-4-~3-nitroph~yl)-1,4-dihydrapyridine-3-carboxylic aîcd.
N.M.R. ~ppm ~CDC~3) : .5.25 (lH, s), 10.50 ~lH, s).
) 2-~thaxyethyl est~r of 5-ethoxycarbonyl-6-~ formyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
. 10 N_~.R. ~ppm tCDCQ3) : 1.14 (t, J-7Hz) } (6H~
1 . Z 6 (t, J~ 7Hz) 2.43 (3H, s), 3.3-3.8 ~4H, m) 9 4,0-4.5 (4H, m~, 5.7-5.8 (lH, m), 6.~-7.0 (lH, m), 7.1-7.8 (4H, m), li 10.27 (lH, s).
16~ 2-Benzyloxye~hyl ester o 5-ethoxycarbonyl-6-~ormyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid.
N.M.R. ~ppm ~CCQ4) : 1.23 (3H) t, J-7.5Hz)~
2.40 (3H, s), 3.4-4.5 (6H, m), 4.41 (2H, s), 5.7-5.8 ~lH, m), 6.8-6.9 (lH, m), 7.2-7.8 (9H, m)~
10.28 (lH, s).
17) 2- ~N-Benzyl-N-methylamirlo~ethyl es~er of S-25 . ethoxycarbonyl-6 -formyl- 4- (2 -trifluoromethylphenyl)-~ 2-methyl-1,4-dihydropyridi~e-3-carboxylic acid.
: : N.M.~. ~ppm (CDCQ3) : 1.23 ~3H9 t, J~7Hz), Z.19`(3H, s), 2.41 (3H, s), 2.63 (2H, t, 3=7Hz), 3.51 (2H, s), :~ 30 . 4-4.4 ~4H, m), 5.71 ~lH, broad~s)~
. 6 .91 (lH, broad s), 7.2-7.7 (~H, m~, 10.28 (lH, s~.
(continued to the ne,xt page) `~ 35 1~:L7 Example 4 A mixture of isopropyl ester of 5-methoxycarbonyl-6-dimethoxymethyl-2-methyl~4-~3-nitrophenyl)-1,4-dihydropyridin-3-carboxylic acid ~11.0 g.) acid (11.0 g.) and 6N hydrochloric acid (11 ml.) in ace-tone ~110 ml.) was stirred at ambient temperature for 4 hours. ~fter removal of the acetone, water ~as added to the reaction mixture and adjusted to pH 7.~
with a saturated aqueous solution of sodium bicarbonate The resultant aqueous solution was e~tracted with ethyl acetate, and the extract was washed with water and dried over anhydrous magnesium sulfate. The removal of the _. solvent gave an oily residue, which was immediately solidified to provide crude yellow-orange crystals of isopropyl ester of 6-formyl-5-methoxycarbonyl-2-methyl-4-~3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid.
N~ppm(CDC13) : 1.13(3H, d, J=7H~), 1.28(3H, d, J=7Hz), 1.79(3H, s), 3.80(3H, s), 5.02(1H, heptet, J=7Hz), 5.27(1H, s), 7.11(1H, broad s), 7.4-8.2(4H, m), 10.60 (lE~, 5) `
(continued to the next page) !
- 19 ' : :
1~7~7 _"
a~l Example 5 1) To a solution of isopropyl ester of 6~formyl-5-methoxycarbonyl-2-me~hyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate (4.2 g) in e~hanol ~85 ml) was gradually added portionwise sodium borohydride (0.409 g) ~VeT a period of 35 minutes under cooling below 0C with stirring. After the reaction mixture was acidified;with 50~ aqueous solution o~ acetic acid, ~he ethanol was removed under reduced pressure. To the resultant aqueous suspension was diluted with water and th~ precipitated pale-yellowish powder was collected by filtration, washed with water and dried. This powder t3-89 g~ was recrystallized with ethanol to give a yellow powder lS t3.05 g) of isopropyl ester of 6-hydroxymethyl-S-methoxycarbonyl-2-methyl-4-(3-nitrophenyl~ 1,4-dihydropyridine-3-carboxylic acid, mp 164-166C.
The following compounds were prepared in substan-~ially the same manner as that of Bxample 5-1).
2) Isopropyl ester of 6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid, mp 132-133C.
3) Isopropyl ester of 6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-4-(2-tolyl~-1,4-dihydropyridine-3-carboxylic acid, mp 134-135.5C.
: 4) Isopropyl ester of 6-hydroxymethyl-S-methoxy-~: carbonyl-2-methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid, mp 182-183C ~dec.).
5) Isopropyl ester of 4-(2-chlorophenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 122-123C.
~: 6) Isopropyl ester o~ 4-(2-tri~luoromethylphenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp lZ3-125, DC.
7) Isopropyl ester of 6-hydroxymethyl-5-methoxy-~ E - 20 7~
~ _J
carbonyl-4-~2-methoxyphenyl~-2-methyl-1~4-dihydro-pyridine-3-carboxylic acid, mp 142-143C.
8) Isop~opyl ester of 4-(2-allyloxyphenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 124-125~C.
9) Isopropyl ester of 6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-4-(2-thienyl~-1,4-dihydropyridine-3-carboxylic acid, mp 124.5-126~C.
10) Isopropyl ester of 4-~2,4-dichlorophenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 150-151C.
11) Isopropyl es~er of 4 (3,4-dichlorophenyl~-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 122-123C.
12) Isopropyl ester of 6-hydroxymethyl-5-me~hoxy-carbonyl-4-(3 7 4-dimethoxyphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 123-124C.
13~ Dipropyl ester o 6-hydroxymethyl-2-methyl-4-~3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid, mp 118-120C.
14) 2-Phenoxyethyl ester of 5-èthoxycarbonyl-4-~2-trifluoromethylphenyl)-6-hydroxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 148-149C.
15) 2-Ethoxyethyl ester of 5-e~hoxycarbonyl-4-~2-trifluoromethylphenyl)-6-hydroxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 65-66.5~C.
16) 2-Benzyloxyethyl ester of 5-ethoxycarbonyl-4-~2-trifluoromethylphenyl)-6~hydroxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 104-106C.
~ 30 ; ~ (continued to t~e next page) ~ ~ .
Example_ 6 1) To a solutiDn of isopropyl ester of 6-formyl-5-methoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1~4-dihydropyridine-3-carboxylic acid (4.5 g) in acetic acid t35 ml) were added hydroxylamine hydrochloride ~0.97 g) and sodium acetate (:L.43 g), and the mixture was stirred at ambient temperature ~or 2.5 hours.
After acetic anhydride (4.14 g~ was added to this reaction mixture, the mixture was stirred at ambient temperature for 1.5 hours and at 95-lOO~C for additional 4 hours. The acetic acid and the excess of acetic anhydride were removed in vacuo, followed by adding water to the residue and it was neutralized with a saturated aqueous solution of sodium bicarbonate.
This aqueous suspension was extracted twice with ethyl acetate, and the combined extract was washed with water, dried over anhydrous magnesium sulfate and evaporated to dryness under reduced pressure to gi~e a redaish-bro~n oil (4.88 g), which was chromatographed o~er silica gel ~150 g) with a mixture of benzene and ethyl acetate (10:1 by volume) as an eluen~ to give a crude crystals (2.99 g). These were recrystallized from ethanol to gi~e yellow prisms (1.89 g) of isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-t3-ni~rophenyl)-1,4-dihydropyridine-3-carboxylic acid, mp 148-150C.
The following compounds were prepared in substan-tially the same manner as that of Example 6-1).
2) Isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid, mp 130-131C.
3) Isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-(2-tolyl)-1,4-dihydropyridi~e-3-carboxylic arid, mp 147-149C.
4) IsopropyI ester of 6-cyano-5-methoxycarbonyl-2-..
~ ~ - E - 22 ,: ' : ~17~;17 4a~
methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid, mp 192-195C ~dec.).
5) Isopropyl ester of 4-(2-chlorophenyl)-6-cyano-S-methoxycarbonyl-2-me~hyl-1,4-dihydropyridine-3-carboxylic acid~ mp 176-177C~
6) Isopropyl ester of 6-cyano-4-(2-trifluoromethyl-phenyl)-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 172-173"C.
7) Isopropyl ester of 6-cyano-5-methoxycarbonyl-4-~2-methoxypheny~-2-methyl-1,4 dihydropyridine-3-carboxylic acid, mp 139-140C.
8) Isopropyl es~er of 4-(2-allyloxyphenyl)-6-cyano-S-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 115 116C.
9) Isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-(2-thienyl)-1,4-dihydropyridine-3-carboxylic acid, mp 129-131C.
10) Isopropyl ester of 4-(2,4-dichlorophenyl)-6-cyano-S-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid~ mp 141-142C.
11) Isopropyl ester o 4-~3j4-dichlorophenyl)-6-cyano-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 159-160C.
12) Isopropyl ester of 6-cyano-5-methoxycarbonyl-4-(3,4-dimethoxyphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 124.5-125.5C.
13) Dipropyl ester of 6-cyano-2-meth~1-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid, mp 138-1409C.
14) 2-Phenoxyethy} ester of 6-cyano-5-ethoxycarbonyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 118-119C.
15) 2-Hydroxyethyl ester of 6-cyano-5-ethoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridi~e-3-carboxylic acid, mp 150.5-152C. ' .
L1'7 '_ a~s 16) 2-E~hoxyethyl ester of 6-cyano-5-ethoxycarbonyl-4-(2-trifluorome~hylphenyl)-~-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 104-105C.
17) 2-Benzyloxyethyl ester o~E 6-cyano-5-ethoxy-S carbonyl-4~2-trifluoromethylph~nyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 146-147.5C.
18) 2-(N-Benzyl-N-methylamino3ethyl ester of 6-cyano-S-ethoxycarbonyl-4-(2-trifluo~omethylphenyl)-2-methyl-1,4-dihydropyridine-3-c~boxylic acid hydro-chloride, mp 203-204C (dec.) (continued to th~ next page) ~, .
~ 25 ~ .
,.
~ .
' ~ 117~L~L 7 ~6 Example 7 To a solution of 2-acetoxyethyl ester o 6-cyano-S-ethoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid ~1.119 g) in ethanol (20 ml) was added dropwise an aqueaus solution (5 ml~
of potassium carbonate (0.346 g) under refluxing and stirring for 2 hours.
After cooling, the ethanol was removed in vacuo from the reaction mixture, followed by neutralizing with acetic acid and extracted twice with ethyl acetate. The combined extract was washed with diluted aqueous solution o sodi~m bicarbonate and an aqueous solution of sodium chloride~ and then dried.
The solven~ was removed in vacuo to gi~e an oil, which was spontaneously crystallized to obtain crystals (0.94 g) of 2-hydroxyethyl ester of 6-cyano-5-ethoxycarbonyl-2-methyl-4-(3-ni~rophenyl)-1,4-dihydropyridine-3-carboxylic acid, mp 150.5-152C.
Exa~E~_~8 A mixture of 2-chloroethyl ester of S-ethoxy-carbonyl-6 diethoxymethyl-4-~2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid ~5.20 g), N-methyl benzylamine ~3.63 g) and sodium iodide (0.2 g) in propyl~alcohol (10 ml) was heated under ~eflux for 4.5 hours. A~ter the solven~ was removed in vacuo from the reaction mixture, water and ethyl acetate were added to the residue. The ethyl acetate layer was separated, washed with water and ~hen dried.
Removal of the solvent gave a residual oil (6.98 g)~
which was chromatographed over silica gel (210 g) with a mix~ure of benze~e and e~hyl aceta~e (5:1 by .
volume) as an e~uent;to give an oil ~3.67 g) of 2-~N-benzyl-N-methylamino)e~hyl ester of 5-etho~ycarbonyl-6-diethoxymethyl-4-t2-trifluoromethylphenyl)-2-mechyl-E ^ 25~
.
r~ 7 ~
` 47 , 1,4~dihydropyridine-3-carboxylic acid.
N.M.R. ~ ppm~CDC13)~ 1.3 t9H,m), 2.17(3H,s), 2.33(3H,s), 2.60(2H,t,J=6Hz), 3.48 (2H,s), 3.4-4.4(8H,m), 5.63 (lH,s),6.13(1H,s), 6.71(lH,s), 7.1 - 7.6 (9H,m).
In this specification the expression "such as" means "for example" and is not in-tended to be construed as limiting.
: .
~: .
.
:~
: : E - 26.
.
. . . ' .. ~
' .
.
1~7~7 _"
a~l Example 5 1) To a solution of isopropyl ester of 6~formyl-5-methoxycarbonyl-2-me~hyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate (4.2 g) in e~hanol ~85 ml) was gradually added portionwise sodium borohydride (0.409 g) ~VeT a period of 35 minutes under cooling below 0C with stirring. After the reaction mixture was acidified;with 50~ aqueous solution o~ acetic acid, ~he ethanol was removed under reduced pressure. To the resultant aqueous suspension was diluted with water and th~ precipitated pale-yellowish powder was collected by filtration, washed with water and dried. This powder t3-89 g~ was recrystallized with ethanol to give a yellow powder lS t3.05 g) of isopropyl ester of 6-hydroxymethyl-S-methoxycarbonyl-2-methyl-4-(3-nitrophenyl~ 1,4-dihydropyridine-3-carboxylic acid, mp 164-166C.
The following compounds were prepared in substan-~ially the same manner as that of Bxample 5-1).
2) Isopropyl ester of 6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid, mp 132-133C.
3) Isopropyl ester of 6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-4-(2-tolyl~-1,4-dihydropyridine-3-carboxylic acid, mp 134-135.5C.
: 4) Isopropyl ester of 6-hydroxymethyl-S-methoxy-~: carbonyl-2-methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid, mp 182-183C ~dec.).
5) Isopropyl ester of 4-(2-chlorophenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 122-123C.
~: 6) Isopropyl ester o~ 4-(2-tri~luoromethylphenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp lZ3-125, DC.
7) Isopropyl ester of 6-hydroxymethyl-5-methoxy-~ E - 20 7~
~ _J
carbonyl-4-~2-methoxyphenyl~-2-methyl-1~4-dihydro-pyridine-3-carboxylic acid, mp 142-143C.
8) Isop~opyl ester of 4-(2-allyloxyphenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 124-125~C.
9) Isopropyl ester of 6-hydroxymethyl-5-methoxy-carbonyl-2-methyl-4-(2-thienyl~-1,4-dihydropyridine-3-carboxylic acid, mp 124.5-126~C.
10) Isopropyl ester of 4-~2,4-dichlorophenyl)-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 150-151C.
11) Isopropyl es~er of 4 (3,4-dichlorophenyl~-6-hydroxymethyl-5-methoxycarbonyl-2-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 122-123C.
12) Isopropyl ester of 6-hydroxymethyl-5-me~hoxy-carbonyl-4-(3 7 4-dimethoxyphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 123-124C.
13~ Dipropyl ester o 6-hydroxymethyl-2-methyl-4-~3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid, mp 118-120C.
14) 2-Phenoxyethyl ester of 5-èthoxycarbonyl-4-~2-trifluoromethylphenyl)-6-hydroxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 148-149C.
15) 2-Ethoxyethyl ester of 5-e~hoxycarbonyl-4-~2-trifluoromethylphenyl)-6-hydroxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 65-66.5~C.
16) 2-Benzyloxyethyl ester of 5-ethoxycarbonyl-4-~2-trifluoromethylphenyl)-6~hydroxymethyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 104-106C.
~ 30 ; ~ (continued to t~e next page) ~ ~ .
Example_ 6 1) To a solutiDn of isopropyl ester of 6-formyl-5-methoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1~4-dihydropyridine-3-carboxylic acid (4.5 g) in acetic acid t35 ml) were added hydroxylamine hydrochloride ~0.97 g) and sodium acetate (:L.43 g), and the mixture was stirred at ambient temperature ~or 2.5 hours.
After acetic anhydride (4.14 g~ was added to this reaction mixture, the mixture was stirred at ambient temperature for 1.5 hours and at 95-lOO~C for additional 4 hours. The acetic acid and the excess of acetic anhydride were removed in vacuo, followed by adding water to the residue and it was neutralized with a saturated aqueous solution of sodium bicarbonate.
This aqueous suspension was extracted twice with ethyl acetate, and the combined extract was washed with water, dried over anhydrous magnesium sulfate and evaporated to dryness under reduced pressure to gi~e a redaish-bro~n oil (4.88 g), which was chromatographed o~er silica gel ~150 g) with a mixture of benzene and ethyl acetate (10:1 by volume) as an eluen~ to give a crude crystals (2.99 g). These were recrystallized from ethanol to gi~e yellow prisms (1.89 g) of isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-t3-ni~rophenyl)-1,4-dihydropyridine-3-carboxylic acid, mp 148-150C.
The following compounds were prepared in substan-tially the same manner as that of Example 6-1).
2) Isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-phenyl-1,4-dihydropyridine-3-carboxylic acid, mp 130-131C.
3) Isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-(2-tolyl)-1,4-dihydropyridi~e-3-carboxylic arid, mp 147-149C.
4) IsopropyI ester of 6-cyano-5-methoxycarbonyl-2-..
~ ~ - E - 22 ,: ' : ~17~;17 4a~
methyl-4-(4-pyridyl)-1,4-dihydropyridine-3-carboxylic acid, mp 192-195C ~dec.).
5) Isopropyl ester of 4-(2-chlorophenyl)-6-cyano-S-methoxycarbonyl-2-me~hyl-1,4-dihydropyridine-3-carboxylic acid~ mp 176-177C~
6) Isopropyl ester of 6-cyano-4-(2-trifluoromethyl-phenyl)-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 172-173"C.
7) Isopropyl ester of 6-cyano-5-methoxycarbonyl-4-~2-methoxypheny~-2-methyl-1,4 dihydropyridine-3-carboxylic acid, mp 139-140C.
8) Isopropyl es~er of 4-(2-allyloxyphenyl)-6-cyano-S-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 115 116C.
9) Isopropyl ester of 6-cyano-5-methoxycarbonyl-2-methyl-4-(2-thienyl)-1,4-dihydropyridine-3-carboxylic acid, mp 129-131C.
10) Isopropyl ester of 4-(2,4-dichlorophenyl)-6-cyano-S-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid~ mp 141-142C.
11) Isopropyl ester o 4-~3j4-dichlorophenyl)-6-cyano-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 159-160C.
12) Isopropyl ester of 6-cyano-5-methoxycarbonyl-4-(3,4-dimethoxyphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 124.5-125.5C.
13) Dipropyl ester of 6-cyano-2-meth~1-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid, mp 138-1409C.
14) 2-Phenoxyethy} ester of 6-cyano-5-ethoxycarbonyl-4-(2-trifluoromethylphenyl)-2-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 118-119C.
15) 2-Hydroxyethyl ester of 6-cyano-5-ethoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridi~e-3-carboxylic acid, mp 150.5-152C. ' .
L1'7 '_ a~s 16) 2-E~hoxyethyl ester of 6-cyano-5-ethoxycarbonyl-4-(2-trifluorome~hylphenyl)-~-methyl-1,4-dihydro-pyridine-3-carboxylic acid, mp 104-105C.
17) 2-Benzyloxyethyl ester o~E 6-cyano-5-ethoxy-S carbonyl-4~2-trifluoromethylph~nyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid, mp 146-147.5C.
18) 2-(N-Benzyl-N-methylamino3ethyl ester of 6-cyano-S-ethoxycarbonyl-4-(2-trifluo~omethylphenyl)-2-methyl-1,4-dihydropyridine-3-c~boxylic acid hydro-chloride, mp 203-204C (dec.) (continued to th~ next page) ~, .
~ 25 ~ .
,.
~ .
' ~ 117~L~L 7 ~6 Example 7 To a solution of 2-acetoxyethyl ester o 6-cyano-S-ethoxycarbonyl-2-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid ~1.119 g) in ethanol (20 ml) was added dropwise an aqueaus solution (5 ml~
of potassium carbonate (0.346 g) under refluxing and stirring for 2 hours.
After cooling, the ethanol was removed in vacuo from the reaction mixture, followed by neutralizing with acetic acid and extracted twice with ethyl acetate. The combined extract was washed with diluted aqueous solution o sodi~m bicarbonate and an aqueous solution of sodium chloride~ and then dried.
The solven~ was removed in vacuo to gi~e an oil, which was spontaneously crystallized to obtain crystals (0.94 g) of 2-hydroxyethyl ester of 6-cyano-5-ethoxycarbonyl-2-methyl-4-(3-ni~rophenyl)-1,4-dihydropyridine-3-carboxylic acid, mp 150.5-152C.
Exa~E~_~8 A mixture of 2-chloroethyl ester of S-ethoxy-carbonyl-6 diethoxymethyl-4-~2-trifluoromethylphenyl)-2-methyl-1,4-dihydropyridine-3-carboxylic acid ~5.20 g), N-methyl benzylamine ~3.63 g) and sodium iodide (0.2 g) in propyl~alcohol (10 ml) was heated under ~eflux for 4.5 hours. A~ter the solven~ was removed in vacuo from the reaction mixture, water and ethyl acetate were added to the residue. The ethyl acetate layer was separated, washed with water and ~hen dried.
Removal of the solvent gave a residual oil (6.98 g)~
which was chromatographed over silica gel (210 g) with a mix~ure of benze~e and e~hyl aceta~e (5:1 by .
volume) as an e~uent;to give an oil ~3.67 g) of 2-~N-benzyl-N-methylamino)e~hyl ester of 5-etho~ycarbonyl-6-diethoxymethyl-4-t2-trifluoromethylphenyl)-2-mechyl-E ^ 25~
.
r~ 7 ~
` 47 , 1,4~dihydropyridine-3-carboxylic acid.
N.M.R. ~ ppm~CDC13)~ 1.3 t9H,m), 2.17(3H,s), 2.33(3H,s), 2.60(2H,t,J=6Hz), 3.48 (2H,s), 3.4-4.4(8H,m), 5.63 (lH,s),6.13(1H,s), 6.71(lH,s), 7.1 - 7.6 (9H,m).
In this specification the expression "such as" means "for example" and is not in-tended to be construed as limiting.
: .
~: .
.
:~
: : E - 26.
.
. . . ' .. ~
' .
.
Claims (90)
1. A process for preparing a compound of the formula:
(I) wherein R1 is phenyl, 3-nitrophenyl, 2-chlorophenyl, 2-trifluoromethylphenyl, 2-methoxyphenyl, 2-allyloxyphenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 2-tolyl, 4-pyridyl or 2-thienyl, R2 is propyl, isopropyl, 2-chloroethyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methyl-amino)ethyl, R3 is lower alkyl, and R4 is di(lower)alkoxymethyl, formyl, hydroxy-methyl or cyano, provided that, when R1 is 3-nitrophenyl, then R2 is 2-hydroxyethyl and R4 is cyano or formyl, or R2 is propyl or isopropyl, and pharmaceutically acceptable salts thereof, which comprises (1) reacting a compound of the formula:
(II-1) wherein R1 and R3 are each as defined above and R? is di(lower)alkoxymethyl, with an amino compound of the formula:
(III-1) wherein R? is as defined below, to give a compound of the formula:
(I-1') wherein R1, R3 and R? are each as defined above, and R? is ispropyl, isopropyl, 2-chloroethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methylamino)ethyl, provided that when R1 is 3-nitrophenyl, then R?
is propyl or isopropyl; or (2) reacting a compound of the formula:
(II-2) wherein R1 and R2 are each as defined above, with an amino compound of the formula:
(III-2) wherein R3 and R? are each as defined above, to give a compound of the formula:
(I-2) wherein R1, R?, R3 and R? are each as defined above, provided that when R1 is 3-nitrophenyl, then R? is propyl or isopropyl; or (3) hydrolysing a compound of the formula:
(I-1) wherein R1, R2, R3 and R? are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl, isopropyl or 2-hydroxyethyl, to give a compound of the formula:
(I-3) wherein R1, R2 and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl, isopropyl or 2-hydroxyethyl; or (4) reducing a compound of the formula:
(I-3) wherein R1, R2 and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl or isopropyl, to give a compound of the formula:
(I-4) wherein R1, R2 and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl or isopropyl; or (5) reacting a compound of the formula:
(I-3') wherein R1 and R3 are each as defined above, and R? is propyl, isopropyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methylamino)ethyl, provided that when R1 is 3-nitrophenyl, then R? is propyl, isopropyl or 2-hydroxyethyl, with hydroxylamine or a salt thereof, and then reacting the resultant product with a dehydrating agent to give a compound of the formula:
(I-5) wherein R1, R? and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R? is propyl, isopropyl or 2-hydroxyethyl; or (6) hydrolysing a compound of the formula:
(IIc) wherein R1 and R3 are each as defined above, and R? is acyl, to give a compound of the formula:
(I-6) wherein R1 and R3 are each as defined above; or (7) reacting a compound of the formula:
(IId) wherein R1, R3 and R? are each as defined above, with N-methyl benzylamine to give a compound of the formula:
(I-7) wherein R1, R3 and R? are each as defined above.
(I) wherein R1 is phenyl, 3-nitrophenyl, 2-chlorophenyl, 2-trifluoromethylphenyl, 2-methoxyphenyl, 2-allyloxyphenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, 2-tolyl, 4-pyridyl or 2-thienyl, R2 is propyl, isopropyl, 2-chloroethyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methyl-amino)ethyl, R3 is lower alkyl, and R4 is di(lower)alkoxymethyl, formyl, hydroxy-methyl or cyano, provided that, when R1 is 3-nitrophenyl, then R2 is 2-hydroxyethyl and R4 is cyano or formyl, or R2 is propyl or isopropyl, and pharmaceutically acceptable salts thereof, which comprises (1) reacting a compound of the formula:
(II-1) wherein R1 and R3 are each as defined above and R? is di(lower)alkoxymethyl, with an amino compound of the formula:
(III-1) wherein R? is as defined below, to give a compound of the formula:
(I-1') wherein R1, R3 and R? are each as defined above, and R? is ispropyl, isopropyl, 2-chloroethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methylamino)ethyl, provided that when R1 is 3-nitrophenyl, then R?
is propyl or isopropyl; or (2) reacting a compound of the formula:
(II-2) wherein R1 and R2 are each as defined above, with an amino compound of the formula:
(III-2) wherein R3 and R? are each as defined above, to give a compound of the formula:
(I-2) wherein R1, R?, R3 and R? are each as defined above, provided that when R1 is 3-nitrophenyl, then R? is propyl or isopropyl; or (3) hydrolysing a compound of the formula:
(I-1) wherein R1, R2, R3 and R? are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl, isopropyl or 2-hydroxyethyl, to give a compound of the formula:
(I-3) wherein R1, R2 and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl, isopropyl or 2-hydroxyethyl; or (4) reducing a compound of the formula:
(I-3) wherein R1, R2 and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl or isopropyl, to give a compound of the formula:
(I-4) wherein R1, R2 and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R2 is propyl or isopropyl; or (5) reacting a compound of the formula:
(I-3') wherein R1 and R3 are each as defined above, and R? is propyl, isopropyl, 2-hydroxyethyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-benzyloxyethyl or 2-(N-benzyl-N-methylamino)ethyl, provided that when R1 is 3-nitrophenyl, then R? is propyl, isopropyl or 2-hydroxyethyl, with hydroxylamine or a salt thereof, and then reacting the resultant product with a dehydrating agent to give a compound of the formula:
(I-5) wherein R1, R? and R3 are each as defined above, provided that when R1 is 3-nitrophenyl, then R? is propyl, isopropyl or 2-hydroxyethyl; or (6) hydrolysing a compound of the formula:
(IIc) wherein R1 and R3 are each as defined above, and R? is acyl, to give a compound of the formula:
(I-6) wherein R1 and R3 are each as defined above; or (7) reacting a compound of the formula:
(IId) wherein R1, R3 and R? are each as defined above, with N-methyl benzylamine to give a compound of the formula:
(I-7) wherein R1, R3 and R? are each as defined above.
2. A process according to claim 1, which comprises reacting a compound of the formula:
(II-1) wherein R1 is as defined in claim 1, R3 is methyl, ethyl or propyl, and R? is dimethoxymethyl, diethoxymethyl or dipropoxymethyl, with an amino compound of the formula:
(III-1) wherein R? is as defined in claim 1 to give a compound of the formula:
(I-1') wherein R1 and R? are each as defined in claim 1, and R3 and R? are each as defined above.
(II-1) wherein R1 is as defined in claim 1, R3 is methyl, ethyl or propyl, and R? is dimethoxymethyl, diethoxymethyl or dipropoxymethyl, with an amino compound of the formula:
(III-1) wherein R? is as defined in claim 1 to give a compound of the formula:
(I-1') wherein R1 and R? are each as defined in claim 1, and R3 and R? are each as defined above.
3. A process according to claim 2, wherein R1 is 3-nitrophenyl, R? is isopropyl, R3 is methyl and R? is dimethoxymethyl.
4. A process according to claim 1, which comprises reacting a compound of the formula:
(II-2) wherein R1 and R? are each as defined in claim 1, with an amino compound of the formula:
(III-2) wherein R3 is methyl, ethyl or propyl, and R? is dimethoxymethyl, diethoxymethyl or dipropoxymethyl, to give a compound of the formula:
(I-2) wherein R1 and R2 are each as defined in claim 1, and R3 and R? are each as defined above.
(II-2) wherein R1 and R? are each as defined in claim 1, with an amino compound of the formula:
(III-2) wherein R3 is methyl, ethyl or propyl, and R? is dimethoxymethyl, diethoxymethyl or dipropoxymethyl, to give a compound of the formula:
(I-2) wherein R1 and R2 are each as defined in claim 1, and R3 and R? are each as defined above.
5. A process according to claim 4, wherein R1 is 3-nitrophenyl, R? is isopropyl, R3 is methyl and R? is dimethoxymethyl.
6. A process according to claim 1, which comprises hydrolysing a compound of the formula:
(I-1) wherein R1 and R2 are each as defined in claim 1, R3 is methyl, ethyl or propyl, and R? is dimethoxymethyl, diethoxymethyl or dipropoxymethyl, to give a compound of the formula:
(I-3) wherein R1 and R2 are each as defined in claim 1, and R3 is as defined above.
(I-1) wherein R1 and R2 are each as defined in claim 1, R3 is methyl, ethyl or propyl, and R? is dimethoxymethyl, diethoxymethyl or dipropoxymethyl, to give a compound of the formula:
(I-3) wherein R1 and R2 are each as defined in claim 1, and R3 is as defined above.
7. A process according to claim 6, wherein R1 is 3-nitrophenyl, R2 is isopropyl, R3 is methyl and R? is dimethoxymethyl.
8. A process according to claim 1, which comprises reacting a compound of the formula:
(I-3') wherein R1 and R? are each as defined in claim 1, and R3 is methyl, ethyl or propyl, with hydroxylamine or a salt thereof, and then react-ing the resultant product with a dehydrating agent to give a compound of the formula:
(I-5) wherein R1 and R? are each as defined in claim 1, and R3 is as defined above.
(I-3') wherein R1 and R? are each as defined in claim 1, and R3 is methyl, ethyl or propyl, with hydroxylamine or a salt thereof, and then react-ing the resultant product with a dehydrating agent to give a compound of the formula:
(I-5) wherein R1 and R? are each as defined in claim 1, and R3 is as defined above.
9. A process according to claim 8, wherein R1 is 3-nitrophenyl, R? is isopropyl and R3 is methyl.
10. A compound of the formula (I) as defined in claim 1, whenever prepared by the process of claim 1 or by an obvious chemical equivalent thereof.
11. A compound of the formula (I-1') as defined in claim 2, whenever prepared by the process of claim 2 or by an obvious chemical equivalent thereof.
12. A compound of the formula (I-1') as defined in claim 3, whenever prepared by the process of claim 3 or by an obvious chemical equivalent thereof.
13. A compound of the formula (I-2) as defined in claim 4, whenever prepared by the process of claim 4 or by an obvious chemical equivalent thereof.
14. A compound of the formula (I-2) as defined in claim 5, whenever prepared by the process of claim 5 or by an obvious chemical equivalent thereof.
15. A compound of the formula (I-3) as defined in claim 6, whenever prepared by the process of claim 6 or by an obvious chemical equivalent thereof.
16. A compound of the formula (I-3) as defined in claim 7, whenever prepared by the process of claim 7 or by an obvious chemical equivalent thereof.
17. A compound of the formula (I-5) as defined in claim 8, whenever prepared by the process of claim 8 or by an obvious chemical equivalent thereof.
18. A compound of the formula (I-5) as defined in claim 9, whenever prepared by the process of claim 9 or by an obvious chemical equivalent thereof.
19. A process according to claim 8, wherein R1 is phenyl, R? is isopropyl and R3 is methyl.
20. A process according to claim 8, wherein R1 is 2-tolyl, R? is isopropyl and R3 is methyl.
21. A process according to claim 8, wherein R1 is 4-pyridyl, R? is isopropyl and R3 is methyl.
22. A process according to claim 8, wherein R1 is 2-chlorophenyl, R? is isopropyl and R3 is methyl.
23. A process according to claim 8, wherein R1 is 2-trifluoromethylphenyl, R? is isopropyl and R3 is methyl.
24. A process according to claim 8, wherein R1 is 2-methoxyphenyl, R? is isopropyl and R3 is methyl.
25. A process according to claim 8, wherein R1 is 2-allyloxyphenyl, R? is isopropyl and R3 is methyl.
26. A process according to claim 8, wherein R1 is 2-thienyl, R? is isopropyl and R3 is methyl.
27. A process according to claim 8, wherein R1 is 2,4-dichlorophenyl, R? is isopropyl and R3 is methyl.
28. A process according to claim 8, wherein R1 is 3,4-dichlorophenyl, R? is isopropyl and R3 is methyl.
29. A process according to claim 8, wherein R1 is 3,4-dimethoxyphenyl, R? is isopropyl and R3 is methyl.
30. A process according to claim 8, wherein R1 is 3-nitrophenyl, and R? and R3 are each propyl.
31. A process according to claim 8, wherein R1 is 2-trifluoromethylphenyl, R? is 2-phenoxyethyl and R3 is ethyl.
32. A process according to claim 8, wherein R1 is 3-nitrophenyl, R? is 2-hydroxyethyl and R3 is ethyl.
33. A process according to claim 8, wherein R1 is 2-trifluoromethylphenyl, R? is 2-ethoxyethyl and R3 is ethyl.
34. A process according to claim 8, wherein R1 is trifluoromethylphenyl, R? is 2-benzyloxyethyl and R3 is ethyl.
35. A process according to claim 8, wherein R1 is 2-trifluoromethylphenyl, R? is 2-(N-benzyl-N-methylamino)ethyl and R3 is ethyl.
36. A process according to claim 1,which comprises reducing a compound of the formula:
(I-3) wherein R1, R2 and R3 are each as defined in claim 1, provided that when R1 is 3-nitrophenyl, R2 is propyl or isopropyl, to give a compound of the formula:
(I-4) wherein R1, R2 and R3 are each as defined above.
(I-3) wherein R1, R2 and R3 are each as defined in claim 1, provided that when R1 is 3-nitrophenyl, R2 is propyl or isopropyl, to give a compound of the formula:
(I-4) wherein R1, R2 and R3 are each as defined above.
37. A process according to claim 36, wherein R1 is 3-nitrophenyl, R? is isopropyl and R3 is methyl.
38. A process according to claim 36, wherein R1 is phenyl, R? is isopropyl and R3 is methyl.
39. A process according to claim 36, wherein R1 is 2-tolyl, R? is isopropyl and R3 is methyl.
40. A process according to claim 36, wherein R1 is 4-pyridyl, R? is isopropyl and R3 is methyl.
41. A process according to claim 36, wherein R1 is 2-chlorophenyl, R? is isopropyl and R3 is methyl.
42. A process according to claim 36, wherein R1 is 2-trifluoromethylphenyl, R? is isopropyl and R3 is methyl.
43. A process according to claim 36, wherein R1 is 2-methoxyphenyl, R? is isopropyl and R3 is methyl.
44. A process according to claim 36, wherein R1 is 2-allyloxyphenyl, R? is isopropyl and R3 is methyl.
45. A process according to claim 36, wherein R1 is 2-thienyl, R? is isopropyl and R3 is methyl.
46. A process according to claim 36, wherein R1 is 2,4-dichlorophenyl, R? is isopropyl and R3 is methyl.
47. A process according to claim 36, wherein R1 is 3,4-dichlorophenyl, R? is isopropyl and R3 is methyl.
48. A process according to claim 36, wherein R1 is 3,4-dimethoxyphenyl, R? is isopropyl and R3 is methyl.
49. A process according to claim 36, wherein R1 is 3-nitrophenyl, and R? and R3 are each propyl.
50. A process according to claim 36, wherein R1 is 2-trifluoromethylphenyl, R? is 2-phenoxyethyl and R3 is ethyl.
51. A process according to claim 36, wherein R1 is 2-trifluoromethylphenyl, R? is 2-ethoxyethyl and R3 is ethyl.
52. A process according to claim 36, wherein R1 is 2-trifluoromethylphenyl, R? is 2-benzyloxyethyl and R3 is ethyl.
53. A process according to claim 1, which comprises hydrolysing a compound of the formula:
(IIc) wherein R1, R? and R3 are each as defined in claim 1, to give a compound of the formula:
(I-6) wherein R1 and R3 are each as defined in claim 1.
(IIc) wherein R1, R? and R3 are each as defined in claim 1, to give a compound of the formula:
(I-6) wherein R1 and R3 are each as defined in claim 1.
54. A process according to claim 53, wherein R1 is 3-nitrophenyl, R? is acetyl and R3 is ethyl.
55. A compound of the formula (I-5) as defined in claim 19, whenever prepared by the process of claim 19 or by an obvious chemical equivalent thereof.
56. A compound of the formula (I-5) as defined in claim 20, whenever prepared by the process of claim 20 or by an obvious chemical equivalent thereof.
57. A compound of the formula (I-5) as defined in claim 21, whenever prepared by the process of claim 21 or by an obvious chemical equivalent thereof.
58. A compound of the formula (I-5) as defined in claim 22, whenever prepared by the process of claim 22 or by an obvious chemical equivalent thereof.
59. A compound of the formula (I-5) as defined in claim 23, whenever prepared by the process of claim 23 or by an obvious chemical equivalent thereof.
60. A compound of the formula (I-5) as defined in claim 24, whenever prepared by the process of claim 24 or by an obvious chemical equivalent thereof.
61. A compound of the formula (I-5) as defined in claim 25, whenever prepared by the process of claim 25 or by an obvious chemical equivalent thereof.
62. A compound of the formula (I-5) as defined in claim 26, whenever prepared by the process of claim 26 or by an obvious chemical equivalent thereof.
63. A compound of the formula (I-5) as defined in claim 27, whenever prepared by the process of claim 27 or by an obvious chemical equivalent thereof.
64. A compound of the formula (I-5) as defined in claim 28, whenever prepared by the process of claim 28 or by an obvious chemical equivalent thereof.
65. A compound of the formula (I-5) as defined in claim 29, whenever prepared by the process of claim 29 or by an obvious chemical equivalent thereof.
66. A compound of the formula (I-5) as defined in claim 30, whenever prepared by the process of claim 30 or by an obvious chemical equivalent thereof.
67. A compound of the formula (I-5) as defined in claim 31, whenever prepared by the process of claim 31 or by an obvious chemical equivalent thereof.
68. A compound of the formula (I-5) as defined in claim 32, whenever prepared by the process of claim 32 or by an obvious chemical equivalent thereof.
69. A compound of the formula (I-5) as defined in claim 33, whenever prepared by the process of claim 33 or by an obvious chemical equivalent thereof.
70. A compound of the formula (I-5) as defined in claim 34, whenever prepared by the process of claim 34 or by an obvious chemical equivalent thereof.
71. A compound of the formula (I-5) as defined in claim 35, whenever prepared by the process of claim 35 or by an obvious chemical equivalent thereof.
72. A compound of the formula (I-4) as defined in claim 36, whenever prepared by the process of claim 36 or by an obvious chemical equivalent thereof.
73. A compound of the formula (I-4) as defined in claim 37, whenever prepared by the process of claim 37 or by an obvious chemical equivalent thereof.
74. A compound of the formula (I-4) as defined in claim 38, whenever prepared by the process of claim 38 or by an obvious chemical equivalent thereof.
75. A compound of the formula (I-4) as defined in claim 39, whenever prepared by the process of claim 39 or by an obvious chemical equivalent thereof.
76. A compound of the formula (I-4) as defined in claim 40, whenever prepared by the process of claim 40 or by an obvious chemical equivalent thereof.
77. A compound of the formula (I-4) as defined in claim 41, whenever prepared by the process of claim 41 or by an obvious chemical equivalent thereof.
78. A compound of the formula (I-4) as defined in claim 42, whenever prepared by the process of claim 42 or by an obvious chemical equivalent thereof.
79. A compound of the formula (I-4) as defined in claim 43, whenever prepared by the process of claim 43 or by an obvious chemical equivalent thereof.
80. A compound of the formula (I-4) as defined in claim 44, whenever prepared by the process of claim 44 or by an obvious chemical equivalent thereof.
81. A compound of the formula (I-4) as defined in claim 45, whenever prepared by the process of claim 45 or by an obvious chemical equivalent thereof.
82. A compound of the formula (I-4) as defined in claim 46, whenever prepared by the process of claim 46 or by an obvious chemical equivalent thereof.
83. A compound of the formula (I-4) as defined in claim 47, whenever prepared by the process of claim 47 or by an obvious chemical equivalent thereof.
84. A compound of the formula (I-4) as defined in claim 48, whenever prepared by the process of claim 48 or by an obvious chemical equivalent thereof.
85. A compound of the formula (I-4) as defined in claim 49, whenever prepared by the process of claim 49 or by an obvious chemical equivalent thereof.
86. A compound of the formula (I-4) as defined in claim 50, whenever prepared by the process of claim 50 or by an obvious chemical equivalent thereof.
87. A compound of the formula (I-4) as defined in claim 51, whenever prepared by the process of claim 51 or by an obvious chemical equivalent thereof.
88. A compound of the formula (I-4) as defined in claim 52, whenever prepared by the process of claim 52 or by an obvious chemical equivalent thereof.
89. A compound of the formula (I-6) as defined in claim 53, whenever prepared by the process of claim 53 or by an obvious chemical equivalent thereof.
90. A compound of the formula (I-6) as defined in claim 54, whenever prepared by the process of claim 54 or by an obvious chemical equivalent thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB39978/78 | 1978-10-10 | ||
| GB7839978 | 1978-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1117117A true CA1117117A (en) | 1982-01-26 |
Family
ID=10500226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000336130A Expired CA1117117A (en) | 1978-10-10 | 1979-09-21 | 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same |
Country Status (10)
| Country | Link |
|---|---|
| JP (2) | JPS5562065A (en) |
| BE (1) | BE879263A (en) |
| CA (1) | CA1117117A (en) |
| CH (1) | CH642353A5 (en) |
| DE (1) | DE2940833A1 (en) |
| FR (1) | FR2438654A1 (en) |
| GB (1) | GB2036722B (en) |
| IT (1) | IT1125469B (en) |
| NL (1) | NL7907482A (en) |
| SE (2) | SE446265B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7910521L (en) * | 1979-12-20 | 1981-06-21 | Haessle Ab | NEW 2-METHYL-6-SUBSTITUTED-4- (2,3-DISUBSTITUTED PHENYL) -1,4-DIHYDROPYRIDINE-3,5-DIESTERS WITH HYPOTHESIVE PROPERTIES, AND PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION |
| JPS57175164A (en) * | 1981-04-18 | 1982-10-28 | Banyu Pharmaceut Co Ltd | 1,4-dihydropyridine derivative and its preparation |
| EP0080220B1 (en) * | 1981-11-17 | 1986-02-19 | FISONS plc | Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals |
| ZA83959B (en) * | 1982-03-10 | 1984-09-26 | Sandoz Ltd | 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them |
| CH655110A5 (en) * | 1982-09-03 | 1986-03-27 | Otsuka Pharma Co Ltd | CARBOSTYRILE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM. |
| DE3312216A1 (en) * | 1983-04-05 | 1984-10-11 | Bayer Ag, 5090 Leverkusen | METHOD FOR PRODUCING SYMMETRIC 1,4-DIHYDROPYRIDINE CARBONIC ACID ESTERS |
| JPS6038322A (en) * | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | Easily soluble solid preparation containing dihydropyridine-a substance |
| GB8412208D0 (en) * | 1984-05-12 | 1984-06-20 | Pfizer Ltd | Quinolone inotropic agents |
| GB8431119D0 (en) * | 1984-12-10 | 1985-01-16 | Fujisawa Pharmaceutical Co | Anti-arteriosclerotic composition |
| GB8602518D0 (en) * | 1986-02-01 | 1986-03-05 | Wyeth John & Brother Ltd | 1 4-dihydropyridines |
| JPS63115890A (en) * | 1986-10-31 | 1988-05-20 | Nippon Shinyaku Co Ltd | 2-substituted 1,4-dihydropyridine derivative |
| ES2043719T3 (en) * | 1987-06-12 | 1994-01-01 | American Cyanamid Co | DRUG ADMINISTRATION BY VIA PERCUTANEA. |
| US5114946A (en) * | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US5045553A (en) * | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| EP0323604B1 (en) * | 1987-12-29 | 1994-05-11 | Fujisawa Pharmaceutical Co., Ltd. | A venous extensibility improving and cardiac hypertrophy suppressant agent containing a dihydropyridine compound |
| DE3888144T2 (en) * | 1987-12-29 | 1994-06-23 | Fujisawa Pharmaceutical Co | Brain neuron protective agent containing a dihydropyridine compound. |
| JP2007230869A (en) * | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | Aldosterone receptor antagonist |
| CN103951608B (en) * | 2009-08-04 | 2016-04-27 | 喜德生(苏州)医药科技有限公司 | Nilvadipine crystal formation and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1552911A (en) * | 1975-07-02 | 1979-09-19 | Fujisawa Pharmaceutical Co | 1,4 dihydropyridine derivatives and the preparation thereof |
| GB1591089A (en) * | 1976-12-17 | 1981-06-10 | Fujisawa Pharmaceutical Co | 1,4-dihydropyridine derivatives and process for preparation thereof |
| DE2658183A1 (en) * | 1976-12-22 | 1978-07-06 | Bayer Ag | 2-POSITION SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A MEDICINAL PRODUCT |
-
1979
- 1979-09-21 CA CA000336130A patent/CA1117117A/en not_active Expired
- 1979-10-08 FR FR7925007A patent/FR2438654A1/en active Granted
- 1979-10-08 BE BE0/197526A patent/BE879263A/en not_active IP Right Cessation
- 1979-10-09 DE DE19792940833 patent/DE2940833A1/en active Granted
- 1979-10-09 SE SE7908367A patent/SE446265B/en not_active IP Right Cessation
- 1979-10-09 IT IT26362/79A patent/IT1125469B/en active Protection Beyond IP Right Term
- 1979-10-09 JP JP13053079A patent/JPS5562065A/en active Granted
- 1979-10-09 GB GB7935022A patent/GB2036722B/en not_active Expired
- 1979-10-09 NL NL7907482A patent/NL7907482A/en active Search and Examination
- 1979-10-10 CH CH912879A patent/CH642353A5/en not_active IP Right Cessation
-
1984
- 1984-02-09 SE SE8400689A patent/SE446096B/en not_active IP Right Cessation
-
1985
- 1985-09-26 JP JP60214152A patent/JPS61118366A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE2940833C2 (en) | 1989-01-26 |
| SE7908367L (en) | 1980-04-11 |
| JPS61118366A (en) | 1986-06-05 |
| SE8400689D0 (en) | 1984-02-09 |
| BE879263A (en) | 1980-04-08 |
| JPS6143343B2 (en) | 1986-09-26 |
| CH642353A5 (en) | 1984-04-13 |
| NL7907482A (en) | 1980-04-14 |
| FR2438654B1 (en) | 1983-01-14 |
| SE8400689L (en) | 1984-02-09 |
| JPS5562065A (en) | 1980-05-10 |
| IT1125469B (en) | 1986-05-14 |
| SE446096B (en) | 1986-08-11 |
| GB2036722A (en) | 1980-07-02 |
| DE2940833A1 (en) | 1980-04-30 |
| JPS6125711B2 (en) | 1986-06-17 |
| SE446265B (en) | 1986-08-25 |
| IT7926362A0 (en) | 1979-10-09 |
| GB2036722B (en) | 1982-12-01 |
| FR2438654A1 (en) | 1980-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1117117A (en) | 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same | |
| CA1239401A (en) | Derivatives of dihydropyridine-3,5-dicarboxylate and pyran-3,5-dicarboxylate | |
| CA1205480A (en) | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them | |
| US4107310A (en) | Quinoline-3-carboxamides | |
| US3985758A (en) | 1,4-Dihydropyridine derivatives | |
| EP0089167B1 (en) | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them | |
| US4346094A (en) | 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels | |
| CA1309098C (en) | Dihydropyridine derivatives, their preparation and their use | |
| JPS6131100B2 (en) | ||
| GB2034693A (en) | Dihydropyridine derivatives | |
| US6506911B2 (en) | Pyrano [3,2-d]-1,3-dioxin-8 ones | |
| AU685876B2 (en) | Branched-amino-substituted thiazoles, processes for their preparation and the pharmaceutical compositions which contain them | |
| GB2158065A (en) | Dihydropyridines | |
| US5288758A (en) | New urea derivatives, their preparation and their application in therapy | |
| CA1330994C (en) | Flavone derivatives | |
| CA2023016A1 (en) | Certain benzopyran and benzothiopyran derivatives | |
| US5116855A (en) | Rhodanine derivatives and pharmaceutical compositions | |
| US4968681A (en) | Substituted hydroxylamines | |
| CA1175825A (en) | Antihypertensive derivatives of 1,4-dihydropyridine | |
| US5095022A (en) | Piperidine derivatives and pharmaceutical compositions comprising the same | |
| US4556739A (en) | 3,4-Dialkoxy-2-alkylcarbonyl analino compounds | |
| JPS61257983A (en) | 1,4-dihydropyridine and medicinal composition | |
| US4544752A (en) | 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels | |
| SK47694A3 (en) | 3-quinolyl substituted dihydropyridines, method of their production, treatments containing these matters, method of their production and using of these compounds | |
| US4505920A (en) | Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |